



HAL
open science

Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy

Thelma Akanchise, Angelina Angelova

► To cite this version:

Thelma Akanchise, Angelina Angelova. Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy. *Pharmaceutics*, 2023, 15 (5), pp.1562. 10.3390/pharmaceutics15051562 . hal-04293943

HAL Id: hal-04293943

<https://hal.science/hal-04293943>

Submitted on 19 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Review

Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy

Thelma Akanchise  and Angelina Angelova * 

Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France;
thelma.akanchise@universite-paris-saclay.fr

* Correspondence: angelina.angelova@universite-paris-saclay.fr

Abstract: Coronavirus infections are neuroinvasive and can provoke injury to the central nervous system (CNS) and long-term illness consequences. They may be associated with inflammatory processes due to cellular oxidative stress and an imbalanced antioxidant system. The ability of phytochemicals with antioxidant and anti-inflammatory activities, such as Ginkgo biloba, to alleviate neurological complications and brain tissue damage has attracted strong ongoing interest in the neurotherapeutic management of long COVID. Ginkgo biloba leaf extract (EGb) contains several bioactive ingredients, e.g., bilobalide, quercetin, ginkgolides A–C, kaempferol, isorhamnetin, and luteolin. They have various pharmacological and medicinal effects, including memory and cognitive improvement. Ginkgo biloba, through its anti-apoptotic, antioxidant, and anti-inflammatory activities, impacts cognitive function and other illness conditions like those in long COVID. While preclinical research on the antioxidant therapies for neuroprotection has shown promising results, clinical translation remains slow due to several challenges (e.g., low drug bioavailability, limited half-life, instability, restricted delivery to target tissues, and poor antioxidant capacity). This review emphasizes the advantages of nanotherapies using nanoparticle drug delivery approaches to overcome these challenges. Various experimental techniques shed light on the molecular mechanisms underlying the oxidative stress response in the nervous system and help comprehend the pathophysiology of the neurological sequelae of SARS-CoV-2 infection. To develop novel therapeutic agents and drug delivery systems, several methods for mimicking oxidative stress conditions have been used (e.g., lipid peroxidation products, mitochondrial respiratory chain inhibitors, and models of ischemic brain damage). We hypothesize the beneficial effects of EGb in the neurotherapeutic management of long-term COVID-19 symptoms, evaluated using either in vitro cellular or in vivo animal models of oxidative stress.

Keywords: Ginkgo biloba bioactive compounds; neuroinvasive coronavirus infection; neurological long COVID; oxidative stress; neuroinflammation; anti-inflammatory and anti-apoptotic agents; nanotherapy; nanoparticle therapeutic efficacy; in vivo and in vitro models



Citation: Akanchise, T.; Angelova, A. Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy. *Pharmaceutics* **2023**, *15*, 1562. <https://doi.org/10.3390/pharmaceutics15051562>

Academic Editors: Maria Bogdan and Liliana Mititelu-Tartau

Received: 23 April 2023

Revised: 17 May 2023

Accepted: 19 May 2023

Published: 22 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Long COVID involves continuous, long-term manifestations of the residual damages and sequelae of coronavirus infection caused by human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a large positive-stranded enveloped RNA virus that generally provokes respiratory diseases [1,2]. SARS-CoV-2 predominantly affects the respiratory system but can also invade the nervous system and cause multiple neurological disorders [3–5]. Patients at risk following COVID-19 infection may still exhibit a range of long-term neurologic and psychiatric disorders (Figure 1) and may not fully recover several months post-infection. These sequelae include mild symptoms, such as headaches; extreme tiredness (fatigue); loss of smell, taste, or tactile sensing functions; cognitive impairment; depression; delirium; and psychosis [5]. More severe documented outcomes include cases of encephalitis, Guillain–Barre syndrome, and stroke [5]. These

long-term neurological problems following SARS-CoV-2 infection have been described as manifestations of post-COVID-19 syndrome, long COVID, long haulers, or the post-acute sequelae of SARS-CoV-2 (PASC) [6,7]. A study performed in Italy found that 87.4% ($n = 179$) of patients who recovered from COVID-19 still report the persistence of at least one symptom, particularly fatigue and dyspnea [8]. Another work reported that the most prevalent symptoms of patients in the 6 months following hospitalization were tiredness (34%), memory/attention problems (31%), and sleep disturbances (30%). Neurological abnormalities were found in 40% of patients who underwent a neurological examination, including hyposmia (18.0%), cognitive impairments (17.5%), postural tremor (13.8%), and mild motor/sensory deficits (7.6%) [9]. Moreover, postmortem studies have established brain tissue edema and partial neuronal degeneration in deceased patients [10].




Figure 1. Long COVID symptoms and prevalence of long-term COVID-19 neurological complications in patients at risk following coronavirus infection. Results obtained from a global online survey. The most frequent symptoms persisted after 3 and 12 months in 216 respondents from a cohort of suspected and confirmed COVID-19 cases. Adapted with permission from [11]. Copyright {2022} Science-HHS Public Access (PubMedCentral).

Due to their neuroinvasive nature, coronaviruses may invade the central nervous system (CNS), causing inflammation and demyelination [12]. According to recent studies, SARS-CoV-2 can reach the CNS in many different ways, including (i) the hematopoietic pathway and subsequent blood–brain barrier (BBB) rupture, (ii) blood–cerebrospinal fluid (B-CSF) distribution, (iii) transsynaptic viral spreading from the peripheral nerve, (iv) via circumventricular organs (CVOs), and (v) olfactory bulb penetration due to the interaction between the virus spike 1 (S1) protein and the angiotensin-converting enzyme 2 (ACE2) receptor [3,13,14]. The latter is widely expressed in neurons, oligodendrocytes, and astrocytes throughout the brain. Additional evidence of these entry pathways has been obtained using genome sequencing and via viral detection in the cerebrospinal fluid (CSF) of several patients [15].

Scientific literature points out three factors that favor the pathogenesis of long COVID: neuroinflammation, thrombosis, and immunosuppression [16,17]. For neurological long COVID sequelae, oxidative stress appears to be the major underlying mechanism. Concurrently, inflammation and thrombosis contribute to reactive oxygen species (ROS) reactivation, resulting in a vicious cycle of oxidative stress, inflammation, and disease progression. According to *in vitro* studies, oxidative stress is a factor in NLRP3-mediated IL-1 release by monocyte cells exposed to SARS-CoV-2 [17]. There is evidence that oxidative stress, caused by an increase in ROS generation after hypoxia, leads to the apoptosis and cellular death of dopamine-containing neurons (DCNs). As a result, Parkinson's disease (PD) may exacerbate as a severe neurodegenerative disorder [18].

Since oxidative stress is intertwined with the onset and pathogenesis of the post-acute sequelae of SARS-CoV-2 infection, harnessing this pathway is a step toward finding new therapeutic options in response to this healthcare challenge. Anti-inflammatory and antioxidant agents may efficiently reduce the complications experienced by patients post-COVID-19. In this context, phytochemicals, such as Ginkgo biloba leaf extract (EGb), have demonstrated significant potential as antiviral agents targeting various stages of the coronavirus life cycle [19,20]. The active constituents of EGb include flavonoids (e.g., quercetin, kaempferol, and isorhamnetin), biflavones (sciadopitysin and ginkgetin), terpene trilactones (ginkgolides and bilobalide), and ginkgolic acids (alkylphenols); see Figure 2.




Figure 2. Primary bioactive compounds in Ginkgo biloba and their pharmacological effects (created with *BioRender* using information from [21,22]). Up and down arrows indicate the upregulation and downregulation of relevant biomarkers, respectively.

It has been shown that EGb 761, a standardized extract that contains bilobalide, 24% flavone glycosides (quercetin, kaempferol, and isorhamnetin), and 6% terpenes, increases the synthesis of INF- γ , while reducing the release of pro-inflammatory cytokines in pe-

ripheral blood leukocytes [22]. Docking simulations and inhibition kinetic studies have demonstrated that ginkgolic acids and bioflavonoids derived from *Ginkgo biloba* exhibit comparatively potent SARS-CoV-2 3CLpro inhibitory capabilities. Thus, several promising leading compounds have been identified for the advancement of antiviral medication research by targeting the 3CLpro enzyme [19]. However, there is currently limited scientific literature on the possible use of EGb nanotherapy for managing long-term neurological problems related to SARS-CoV-2 or an overview of several models to evaluate the therapeutic outcome of EGb. Recent studies on *Ginkgo biloba* have examined the efficiency of various EGb extracts against age-related disorders, including dementia, Alzheimer's disease, and mild cognitive impairment (MCI). These studies include those by Barbalho et al., Singh et al., and Tomino et al. [23–25]. Al-Kuraishy et al., however, discussed the use of EGb in managing COVID-19 severity but did not thoroughly review the effectiveness of EGb nanotherapies [26].

This review gives a comprehensive overview of the potential uses of *Ginkgo biloba* as an antiviral, anti-inflammatory, and antioxidant agent capable of regulating the neurological complications of SARS-CoV-2 infection. We summarize the reported findings of *in vivo* and *in vitro* models mimicking oxidative stress conditions and aiming at the discovery of novel nanotherapeutics based on *Ginkgo biloba* ingredients. We hypothesize that the presented results can be of interest to the neurotherapeutic management of long COVID.

2. Long-Term Neurological Damage and the Role of Oxidative Stress

2.1. Neuroinvasive and Neurotoxic Potential of Coronavirus Linked to Neurodegeneration

The CNS has been proven to be susceptible to viral infections [3,4,27,28]. A series of recent studies have demonstrated the neuroinvasive potential of SARS-CoV-2, like the previously established neurovirulence of human coronaviruses, such as SARS-CoV, MERS-CoV, HCoV-229E, and HCoV-OC43 [28–32]. According to Boroujeni et al., COVID-19 impacts the cerebral cortex of patients. This effect is characterized by activated microglia that amplify the inflammatory activation of astrocytes and is accompanied by low glutathione levels and upregulation of inflammation [33]. Palpagama et al. asserted that the activation of glial cells is involved in the pathology of neurodegenerative disorders [34]. The elevated number of such cells can be associated with neuroinflammation and brain tissue damage.

Other researchers have detected the presence of SARS-CoV-2 RNA in the cerebrospinal fluid after the virus infects the patient's CNS and causes meningitis and encephalitis [10,32,35,36]. Alternatively, evidence has revealed that 50% of patients with COVID-19 develop intestinal inflammation [37–39]. These results support the gut-driven inflammation hypothesis of Parkinson's disease (PD) pathogenesis, which starts in the intestines and advances through inflammation toward the CNS. The associated increased levels of α -synuclein initiate aggregation in the gut and brain [40]. Magnetic resonance imaging (MRI) data have also shown brain alteration in the cortical region (posterior gyrus rectus) that is associated with olfaction. This fact suggests that SARS-CoV-2 can invade the brain through the olfactory pathway and cause olfactory dysfunction, among other neurological disorders [41]. Additionally, olfaction-related brain changes in the posterior gyrus rectus of the brain have been observed using magnetic resonance imaging (MRI) [41]. This finding suggests that SARS-CoV-2 can enter the brain via the olfactory pathway and induce neurological diseases, such as olfactory impairment and other neurological conditions.

It is hypothesized that the neuroinvasive potential of SARS-CoV-2 plays a subordinate role in the pathogenesis of long COVID [4,42–44]. The virus enters the CNS and the PNS via the engagement of hematogenous or transsynaptic pathways (through the nasal cavity or the bloodstream) and triggers neuroinflammation [45]. As shown in Figure 3, SARS-CoV-2 invades the host cells by binding to the ACE2 receptor with its spike (S) protein and then priming with the S protein through the activities of the transmembrane protease, serine 2 (TMPRSS2) [46]. ACE2 is highly expressed in the brain of humans and animals, notably in some brain locations, such as the choroid plexus and paraventricular nuclei of the thalamus and in non-neuron cells (mainly astrocytes and oligodendrocytes)

as well as various vessel calibers in the frontal cortex [47]. The presence of ACE2 in primary human brain microvascular endothelial cells (hBMVECs) alleviates the ability of SARS-CoV-2 to compromise the activity of the BBB [47,48]. Coronavirus infections are primarily associated with cytokine production, inflammation, and apoptosis in accordance with the pathophysiological process of oxidative stress [49].




Figure 3. The hypothesized mechanism of coronavirus-induced neuronal damage via oxidative stress and mitochondria dysfunction. SARS-CoV-2 infection occurs when TMPRSS2 primes the spike proteins for proteolysis, allowing the binding to ACE2. The affinity interaction triggers the binding of Ang II to the angiotensin type 1 receptor (AT1R), activating NADPH oxidase. This leads to mitochondrial electron transport chain (ETC) damage via the release of oxidative and nitrosative species, subsequently increasing the formation of mitochondrial reactive oxygen species (mtROS). The signaling pathways mediated by mtROS trigger the production of inflammatory cytokines, which can compromise the blood–brain barrier, thus resulting in neuronal damage. Additionally, mtROS cause nuclear and mitochondrial damage, which prolongs mitochondrial dysfunction and encourages inflammatory senescence (created with BioRender).

2.2. Oxidative Stress and Redox Signaling, Players in SARS-CoV-2 Neurological Damage

It has been shown that Parkinson’s disease and SARS-CoV-2 infection cause similar oxidative stress and the activation of nuclear factor kappa B (NF- κ B) [18,50,51]. In addition, activating pro-inflammatory mediators, such as IL-1 and IL-6, can lead to amyloid beta (A β) deposition and accumulation, thus establishing a link between neuroinflammation and Alzheimer’s disease [14,52,53].

It has been demonstrated that the receptor-binding domain (RBD) of the SARS-CoV-2 spike 1 (S1) protein binds to A β and tau proteins and causes their aggregation [54]. Additionally, SARS-CoV-2 infection has been linked to hypoxia and decreased oxygen levels [53]. The mitochondria of brain cells may undergo a rise in anaerobic metabolism due to this process, which can increase the levels of lactic acid, lipid peroxides, and oxygen-free radi-

cals and deplete the antioxidant system. Consequently, the BBB is compromised, which may result in CNS complications. [36,49].

In regard to the role of oxidative stress in chronic diseases, Aranda-Rivera et al. highlighted the importance of nuclear factor erythroid 2-related factor 2 (Nrf2), a ubiquitous protein (containing 605 amino acids) that can modulate cellular oxidative stress [55]. During oxidative stress, Keap1 undergoes conformational change due to the oxidation of residues Cys 226, Cys 613, and Cys 624 by electrophiles and oxidants [56]. This mechanism enables Nrf2 to escape ubiquitination, leading to its release into the nucleus and regulating the expression of a number of antioxidant and detoxifying enzymes, such as glutamate-cysteine ligase modifier (GCLM) subunits, heme oxygenase, NAD(P)H quinone dehydrogenase 1 (NQO1), glutathione S-transferase, and glutathione peroxidase [57,58].

It should also be emphasized that viral infections, such as SARS-CoV-2, have adverse effects on antioxidant systems and have been linked to phenomena involving the inhibition of Nrf2 and activation of the NF- κ B pathway in favor of inflammation and oxidative stress. Olganier et al. showed that during SARS-CoV-2 infection, the Nrf2 pathway is repressed, leading to the downregulation of heme oxygenase 1 (HO-1) and NQO1 [59]. Therefore, several antioxidant enzymes that guard against oxidative stress, including glutathione peroxidase, peroxiredoxin, thioredoxin reductase, and thioredoxin, are affected.

Numerous studies have shown that the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway controls oxidative stress by activating the transcription factor FOXO3 and initiating the transcription of antioxidant proteins, such as SOD-2, peroxiredoxins (PRDXs) 3 and 5, which are found in the mitochondria, and catalase, which is found in the peroxisomes [60–62]. Peroxisome-proliferator-activated receptor coactivator 1 (PGC-1), the master biogenesis regulator that promotes the transcription of antioxidant enzymes, interacts with the FOXO3 transcription factor to control oxidative stress in the mitochondria [61]. However, research has revealed that the ability of PGC-1 to promote gluconeogenesis and fatty acid oxidation is inhibited by protein kinase Akt2/protein kinase B (PKB), which acts as an intermediary trigger of phosphorylation and inhibition [62].

NF- κ B is another transcription factor that regulates stress responses. It is activated by the phosphorylation of I- κ B, thanks to the I- κ B kinase (IKK) complex. In vitro studies by Wu et al. have reported that sustained exposure of human lens epithelial cells (HLECs) to increasing doses of H₂O₂ (50–100 μ M) for 4 h attenuates the TNF α -induced degradation of I- κ B, accompanied by the activation of NF- κ B and proteasome activity by 50–80% [63]. The obtained data have also indicated that the activation of NF- κ B is an essential phenomenon that enables cells to recover from oxidative stress.

2.3. In Vivo and In Vitro Models of Oxidative Stress

Over the years, various oxidative stress models have been developed to study the pathogenesis of neurodegenerative disorders and discover new strategies for developing therapeutic agents. Such experimental techniques include the use of lipid peroxidation products, endogenous antioxidant depletion, mitochondrial respiratory chain inhibitors, neurotoxic agents (e.g., rotenone and *N*-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)), and ischemic brain damage models [51]. The proposed in vitro cellular models and in vivo animal models have shed light on the molecular mechanisms underlying oxidative stress responses in the nervous system, such as cell survival and cell death. Among neurotoxic chemical agents, 6-hydroxydopamine (6-OHDA) has been used to induce neurotoxicity in the dopaminergic nigrostriatal system by inhibiting the mitochondrial electron transport chain of complexes I and IV and accelerating neuronal degeneration [64–66].

6-OHDA has been regarded as an endogenous toxic factor in the pathogenesis of PD. The neurotoxin 6-OHDA induces excessive production and accumulation of ROS and, therefore, oxidative stress. In fact, 6-OHDA induces caspase-3 activation in the cells mediated by the Fas or mitochondrial pathways [67]. Indeed, it has been demonstrated that MPTP/6-OHDA-induced NF- κ B activation in SH-SY5Y neuroblastoma cells triggers caspase-3 activation, which results in the death of DCNs via the NF- κ B pathway [68–70].

In vitro studies have evaluated the toxic effects of 6-OHDA in dopaminergic (DAergic) cell cultures. For instance, Vestuto et al. used human neuroblastoma SH-SY5Y cells to assess the neuroprotective effect of cocoa extract (purified fractions) in a 6-OHDA-induced PD cellular model [71]. Similarly, Chansiw et al. reported the protective effect of 1-(*N*-acetyl-6-aminoethyl)-3-hydroxy-2-methyl pyridine-4-one (CM1) coupled with green tea extract (GTE) on iron-induced oxidative stress in SH-SY5Y cells [72]. In a separate study, Chen et al. evaluated the protective effect of EGCG against 6-OHDA-induced neurotoxicity by using N27 dopaminergic neurons [73].

The advantages of cellular systems for studying oxidative stress are their low cost, adaptability, modularity, reproducibility, compatibility with high-throughput screening, and interest in cell mechanical investigations without systemic interferences. Other studies have demonstrated that hypoxia can increase cells' susceptibility to oxidative stress. The hypoxia-reoxygenation model is a relevant in vitro model of oxidative stress, given that cellular hypoxia appears to be a crucial signal that activates transcriptional regulators, specifically hypoxia-inducible factor-1 (HIF-1) [74], nuclear factor kappa B (NF- κ B) [75], activator protein 1 (AP-1) [76,77], and some mitogen-activated protein kinase (MAPK) signaling pathways, and induces cell death and necrosis [76,77].

Genetically derived models of neurodegenerative diseases are gaining considerable interest because they are excellent surrogates, providing intrinsic validity to genetically based models of degenerative disorders [78]. Scientific investigations have reported that knockout of genes, including PINK1, DJ-1, LRRK2, and LRRK1, in rats leads to age-dependent neurodegeneration of the dopaminergic neurons of PD [78–80]. Moreover, mutation in the copper-zinc superoxide dismutase 1 (SOD1) gene has been associated with ALS, while the alteration of MAPT genes or progranulin is linked to frontotemporal dementia (FTD) [81]. Other studies have highlighted that mutations in amyloid precursor protein (APP), presenilin 1, and presenilin 2 (PSEN1/2) are the main causes of autosomal dominant early-onset AD [82,83].

It has been documented that invertebrates can also mimic endogenous-generated ROS. Such a model has been widely implemented in *Drosophila melanogaster* and *Caenorhabditis elegans* (*C. elegans*) [84,85]. The initial longevity mutant, known as age-1, which contains increased levels of both SOD1 and catalase, is arguably the best-studied mutant in the nematode *C. elegans*. The age-1 mutant exhibits more significant levels of both SOD1 and catalase enzymes because this gene, which encodes for phosphatidylinositol-3 kinase, confers a longer lifetime phenotype when silenced, along with improved resilience to several forms of stress [85–87].

The aforementioned findings indicate that oxidative-stress-based pharmaceutical therapies can slow aging and degeneration, as summarized in Table 1. Therefore, the developed in vivo and in vitro models of oxidative stress can be of interest for evaluating the efficacy of nanotherapeutic management of long COVID conditions.

Table 1. Stimuli that trigger oxidative stress in cells or in the CNS, similar to the SARS-CoV-2 action.

Stimuli	Model/Species	Disease Model	Administration/Protocol	Mechanism of Oxidative Stress	Ref.
<i>N</i> -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)	Male C57BL/6 mice (20–25 g)	PD, neurodegeneration	Intraperitoneal injection of MPTP (20 mg/kg), two times at 4 h intervals daily for 5 days, followed by oral administration of <i>Sophora tomentosa</i> (25 mg/kg, 50 mg/kg, and 100 mg/kg) for 15 consecutive days until behavioral tests	<ul style="list-style-type: none"> MPTP is taken up by astrocytes or serotonergic neurons, where it is metabolized into 1-methyl-4-pyridinium (MPP+) by monoamine oxidase B. Subsequent uptake of MPP+ via dopamine, serotonin, and norepinephrine transporters induces oxidative stress by inhibiting complex I of the respiratory chain. Selectively destroys the nigrostriatal dopaminergic pathway and thus is widely used as a PD model. Upregulates levels of MDA, α-synuclein overexpression, and GSK-3β phosphorylation in the mouse striatum. 	[88]

Table 1. Cont.

Stimuli	Model/Species	Disease Model	Administration/Protocol	Mechanism of Oxidative Stress	Ref.
Rotenone	Rotenone-induced Sprague–Dawley and Lewis rats	PD	Infusion of a 2–3 mg/kg dose of rotenone per day via a jugular vein cannula attached to a subcutaneous osmotic minipump	<ul style="list-style-type: none"> Inhibits of complex I and degenerates the nigrostriatal dopaminergic pathway associated with hypokinesia and rigidity. 	[89]
Paraquat (<i>N,N'</i> -dimethyl-4-4'-bipyridinium)	Human neuroblastoma SH-SY5Y cells	PD	Treated with paraquat (0.5 mM PQ) for 48 h	<ul style="list-style-type: none"> Increases superoxide levels and neuronal cell death. Decreases dopamine levels in the substantia nigra and increases α-synuclein expression. Decreases protein levels of Nrf2, γGCS levels, and intracellular GSH levels. 	[90]
Hydrogen peroxide (H_2O_2)	SH-SY5Y cells	PD, AD, Huntington's disease	Incubation with varying concentrations of H_2O_2 (0 to 250 μ M) for 30 min, followed by evaluation of cell viability	<ul style="list-style-type: none"> Loss of viability <5% at concentrations up to 250 μM H_2O_2. Cell membrane and DNA damage accompanied by decreased SOD activity but increased GPX activity in cells treated with >50 μM concentration of H_2O_2. 	[91,92]
6-hydroxy dopamine (6-OHDA)	SH-SY5Y cells	PD, AD, and dementia	Cells incubated with 200 μ M of 6-OHDA for 24 h with or without hyperoxide or NAC pretreatment	<ul style="list-style-type: none"> Inhibits both complexes I and IV of the respiratory chain and leads to the generation of superoxide, hydrogen peroxide, and hydroxyl radicals. 	[93]
Glutamate analog; homocysteate quisqualate ibotenate	Neuronal hybridoma cell line, N18-RE-105 mouse neuroblastoma cells	ALS, AD, dementia, PD, multiple sclerosis (MS)	Continuous exposure of cells to L-glutamate (1–10 mM) or quisqualate (0.1–1.0 mM) for 5 min	<ul style="list-style-type: none"> Induces cytotoxicity by inhibiting cystine uptake and resulting in lowered glutathione levels, leading to oxidative stress and cell death. 	[94,95]
Mycotoxin 3-nitropropionic acid (3-NP)	Male Wistar rats (300–350 g)	Huntington disease	Intraperitoneal administration of 3-NP (10 mg/kg)	<ul style="list-style-type: none"> Irreversibly inhibits the Krebs cycle and complex II of the respiratory chain. Promotes the generation of hydroxyl radicals, leading to neuronal death. Induces motor dysfunction. 	[96]
Buthionine sulfoximine (BSO)	Hippocampus-derived immortalized cell line (HT22)	Chronic psychological stress	Treatment with 1 mM BSO for 14 h	<ul style="list-style-type: none"> Binds to glutathione synthetase to inhibit glutathione production. 	[97]
Tunicamycin	SH-SY5Y cells	Endoplasmic reticulum stress	Incubation with 1 μ M tunicamycin	<ul style="list-style-type: none"> Intracellular accumulation of aggregates of misfolded protein. 	[98]
RNAi	Drosophila	Oxidative damage	Knockdown of SOD2 using the Gal4/UAS system to express SOD2 inverted repeat (<i>Sod2-IR</i>) transgenes	<ul style="list-style-type: none"> Degrades mRNA related to the expression of a specific antioxidant. Increases caspase activity, decreases mitochondrial content, and reduces ATP levels. 	[99]

3. Ginkgo Biloba Extract (EGb) for Neuroprotection and Potential Regeneration from Long COVID Syndrome

3.1. Ginkgo Biloba Antioxidative and Anti-Inflammatory Effects

Ginkgo biloba (GB) is one of the medicinal plants that ameliorate capillary blood circulation, provide brain oxygenation, and thus improve age-related disorders. The ginkgo tree is monotypic and belongs to the class Ginkgoopsida, considered the oldest tree alive in the world (ginkgo species are from the Permian period, around 286–248 million years ago) [23]. The currently available herbal medicines based on Ginkgo biloba extract (EGb) are Tebonin[®] and Tanakan[®], which are mostly standardized on ginkgo flavone glycosides and terpene lactones—EGb 761[®] [26]. The standardized extract of Ginkgo biloba leaves includes 6% terpenoids, of which 3.1% are ginkgolides A, B, C, and J and 2.9% are bilobalide. It contains 24% flavonoid glycosides, including quercetin, kaempferol, and isorhamnetin, and 5–10% organic acids (Figure 2) [100]. Ginkgo biloba leaf extract is

mentioned in the *British Herbal Compendium* as a treatment for mild-to-severe dementia, including Alzheimer's disease, and for the treatment of neurological symptoms attributed to loss of concentration and poor memory, confusion, depression, anxiety, vertigo, tinnitus, and headache [101].

The neuroprotective effect of EGb 761 extract has been examined in a rat model of cerebral injury following ischemia/reperfusion (I/R). The treatment resulted in a decrease in MDA levels, the downregulation of pro-inflammatory cytokines (TNF- α and IL-1 β), and an increase in the expression of anti-inflammatory cytokines (IL-10) and enzymatic SOD and myeloperoxidase (MPO) activities, which can control neurological impairments [102]. It can be suggested that the beneficial effects of EGb on cerebral ischemia/reperfusion I/R injury result from the reduction in oxidative stress due to the inhibition of nitric oxide production and inflammation induced by I/R [102].

Kaempferol is one of the most important constituents of Ginkgo biloba, and its action accounts for the upregulation of the glutamate-cysteine ligase catalytic (GCLC) subunit, brain-derived neurotrophic factor (BDNF), B-cell lymphoma protein 2 (Bcl-2), and GSH [103–105]. Kaempferol inhibits ROS generation by scavenging free radicals and efficiently protects neuronal cells from oxidative injury. Additionally, it inhibits the production of pro-apoptotic proteins, including Bax and caspase-3, and modulates the downregulation of the NF- κ B pathway to exert anti-apoptotic effects [106]. A study by Zhou et al. showed that kaempferol can inhibit mitochondrial membrane transition (mPTP) opening and suppresses the release of cytochrome C via GSK-3 β inhibition [107]. Kaempferol is also involved in the inhibition of serotonin breakdown by monoamine oxidase, reduces neurotoxicity induced by 3-nitropropionic acid (3-NP), and induces the upregulation of heme oxygenase 1 (HMOX-1) [108].

Quercetin, bilobalide, and isorhamnetin are other essential compounds in Ginkgo biloba extracts. Bilobalide decreases the expression of reactive species induced through H₂O₂, thus inhibiting ER stress [109]. It can also suppress pro-inflammatory activation, NF- κ B, and COX-2 activities [110]. Studies have reported the beneficial effects of bilobalide in the upregulation of c-myc and p53 proteins, inhibition of the degradation of membrane phospholipids, and increased cellular proliferation of neurons in the hippocampus [109,111,112]. According to Wang et al., pretreatment with bilobalide substantially reduced COX-2, iNOS, and phosphorylated p65 in sepsis-induced CLP mouse models, while inducing I- κ B activation in the lungs [111]. Additionally, bilobalide reduced oxidative stress by increasing HO-1 expression in lung tissues and antioxidative enzyme genes, including catalase, MnSOD, CuZnSOD, and GPx-1 [111]. Moreover, bilobalide and EGb50 can modulate the expression of TLR4, NF-B, and MyD88, preventing the onset of acute lung injury (ALI) [111,113,114]. Ginkgo biloba components may therefore prevent the onset of ALI and the cytokine storm syndrome in COVID-19 by inhibiting pro-inflammatory signaling via the NF- κ B and TLR4 signaling pathways. A study showed that the administration of EGb50 substantially lowers TNF- and IL-1 levels and prevents the related signal transduction through the p38 MAPK and NF-B p65 pathways in LPS-stimulated microglial cells [115]. In a separate study, EGb50 demonstrated a potential anti-inflammatory action by suppressing NLRP3-inflammasome-induced microglial activation [116]. For comparison, isorhamnetin has been linked with the inhibition of apoptosis and the suppression of DNA fragmentation [117].

In an enzymatic inhibition assay, it was established that ginkgolide A can act as an irreversible inhibitor against SARS-CoV-2 papain-like protease (PLpro) at a nontoxic dose of 1.79 μ M [20]. Similarly, quercetin, the primary EGb flavonoid component, inhibits SARS-CoV-2 3-chymotrypsin-like protease (3CLpro) and PLpro, with a corresponding docking energy of 6.25–4.62 kcal/mol, preventing SARS-CoV-2 replication [118].

In a recent study, Liu et al. compared the antioxidant capacity of various Ginkgo biloba extracts by evaluating the mechanisms of ginkgolides A (GA), B (GB), K (GK), and bilobalide (BB) against oxidative stress caused by transient focal cerebral ischemia [119].

In vivo studies have been performed in a developed middle cerebral artery occlusion (MCAO) model of cerebral ischemic injury using male SD rats, followed by reperfusion and Ginkgo biloba treatments [119]. Neuroblastoma cells (SH-SY5Y) were subjected to oxygen-glucose deprivation (OGD) for 4 h, followed by 6 h of reoxygenation using ginkgolides and bilobalide. The in vitro experimental findings revealed that GA, GB, GK, and BB significantly reduce ROS and increase SOD activities and protein levels, including HO-1 and Nqo1. Additionally, p-Akt and p-Nrf2 levels considerably increased following ginkgolide and BB treatments, with GB demonstrating greater efficacy than GA and GK. These up-regulations could be reduced in a dose-dependent manner by LY294002, a PI3K inhibitor. The triphenyl tetrazolium chloride (TTC) staining performed demonstrated that GB significantly reduced the infarct volume ratios in MCAO rats in a dose-dependent manner (Figure 4a). Additionally, GB markedly increased the amounts of the proteins HO-1, Nqo1, SOD, p-Akt, p-Nrf2, and Nrf2 through the modulation of the Akt/Nrf2 signaling pathway, shielding neurons from oxidative-stress-related damage (Figure 4b) [119].




Figure 4. Effects of Ginkgo biloba on infarct volume and expression of proteins associated with antioxidant effects in middle cerebral artery occlusion (MCAO) rat models. **(A)** MCAO rats were treated with various GB doses for 72 h, followed by triphenyl tetrazolium chloride (TTC) staining and statistical analysis of the cerebral infarct area. The results revealed a significant reduction in infarct volume ratios after GB treatments in a dose-dependent manner. **(B)** Results of Western blot analysis and semi-quantitative measurements of the levels of HO-1, Nqo1, and SOD1 proteins in the ischemic penumbra region of MCAO rats treated with various doses of Ginkgo biloba for 24 h. Antioxidant-related proteins in the MCAO group drastically decreased after cerebral ischemic injury compared to the normal group, while rats treated with various concentrations of GB showed a marked increase in the expression of HO-1, Nqo1, and SOD1. Data represented as the mean \pm SD from eight rats of each group. (# $p < 0.05$, ## $p < 0.01$, and ### $p < 0.001$ vs. the sham group; * $p < 0.05$ and *** $p < 0.001$ vs. the I/R group). Adapted with permission from [119]. Copyright {2019} Science-HHS Public Access (PubMedCentral).

Table 2 summarizes the chemical structures of the active constituents identified in Ginkgo biloba extracts and their reported biological activities of potential interest to recovery from neurological long COVID syndrome.

Table 2. Chemical structures of bioactive compounds extracted from Ginkgo biloba sources and their effects on neurological disorders linked to COVID-19.






Compound	Sources	Activity/Mechanism	Ref.																
 <table border="1" data-bbox="119 795 518 918"> <thead> <tr> <th>Ginkgolide</th> <th>R1</th> <th>R2</th> <th>R3</th> </tr> </thead> <tbody> <tr> <td>A</td> <td>-H</td> <td>-OH</td> <td>-H</td> </tr> <tr> <td>B</td> <td>-H</td> <td>-OH</td> <td>-OH</td> </tr> <tr> <td>C</td> <td>-OH</td> <td>-OH</td> <td>-OH</td> </tr> </tbody> </table>	Ginkgolide	R1	R2	R3	A	-H	-OH	-H	B	-H	-OH	-OH	C	-OH	-OH	-OH	Leaves, root, and bark	<ul style="list-style-type: none"> • Anti-inflammatory actions by decreasing the expression of TNF-α, IL-1β, and NF-κB • Antioxidant effects by inhibiting free radicals • Anxiolytic-like effects • Coffer neuroprotection by regulating pathways related to neurodegeneration and inflammation • Anti-thrombotic action in inhibiting platelet aggregation by MMP-9 • Controlling cAMP, thereby inhibiting intracellular Ca²⁺ mobilization and decreasing TXA₂ activity • Inhibited activation factor of platelets and signaling pathways, such as NIK/IKK α/I-κB/NF-κB • Activation of the p42/p44 (ERK) MAPK pathways, effect on mRNA levels and the protein from HIF-1α 	[120–126]
Ginkgolide	R1	R2	R3																
A	-H	-OH	-H																
B	-H	-OH	-OH																
C	-OH	-OH	-OH																
	Leaves and bark	<ul style="list-style-type: none"> • Decreased TNF-α, IL-1β, and IL-6 levels • Neuroprotection by reducing neuroinflammation and preventing Aβ deposition in AD • Antioxidant effects by decreasing ROS • Modulation of Bax, c-myc, and p53 proteins • Activated Nrf2 and CREB through the PI3K/Akt signaling pathway, thus inhibiting apoptotic damage of nerve cells 	[119,127,128]																
	Leaves	<ul style="list-style-type: none"> • Improved brain function and cognition • Anti-inflammatory/antioxidant properties • Decreased apoptosis and DNA fragmentation • Cleavage of PARP, impact on the ERK pathway and the activation of p53 protein • Upregulation of genes related to Bcl-2 • Downregulation of the BH3 gene and genes related to Bax 	[117,129–131]																
	Leaves	<ul style="list-style-type: none"> • Neuroprotection against Aβ-induced impairment of neurotransmitter release and synaptic plasticity • Antiviral and antibacterial effects by suppressing the fusion of enveloped viruses, including SARS-CoV-2 • Promotion of autophagy-dependent clearance of α-syn aggregates 	[132,133]																
	Leaves	<ul style="list-style-type: none"> • Upregulated BDNF levels • Inhibited degradation of serotonin by monoamine oxidases • Impact on the transcription of TNF-α • Activation of ERK and JNK • Decreased lipid peroxidation in the plasma and phosphorylation of I-κB • Upregulation of HMOX-1 • Free-radical elimination 	[129,134–136]																

Table 2. Cont.

Compound	Sources	Activity/Mechanism	Ref.
Luteolin	Leaves	<ul style="list-style-type: none"> • Anti-inflammatory effect by suppressing TNF-α, IL-6, COX-2, and NF-κB expression • Antioxidant effect by scavenging ROS • Neuroprotective action by inhibiting Aβ deposition and augmenting neuroinflammation in the brain 	[137,138]
Kaempferol	Leaves	<ul style="list-style-type: none"> • Upregulation of GSH and suppression of oxidative and inflammatory damage to brain cells • Inhibition of NF-κB, COX-2, and iNOS expression • Protection against ischemia/reperfusion syndrome and myocardial injury • Upregulation of BDNF, GCLC, and Bcl-2 levels • Decrease in neurotoxicity induced via 3-NP, elevation of Bax, and upregulation of HMOX-1 	[104,105,107]

3.2. Neuroprotective, Anti-Apoptotic, and Anxiolytic Drug Effects of EGb

Results from microarray experiments have established the neuroprotective effect of Egb 761 against ischemic-induced neuronal injury [139]. The data revealed that the upregulation of Bcl-2 protein may be mediated by the activation of cAMP-response-element-binding protein (CREB) [139]. EGb 761 increases CREB phosphorylation via the activation of PI3K/Akt and extracellular-signal-regulated kinase (ERK) signaling pathways [140]. The consequently released BDNF protects the neurons against ischemia. Moreover, Tchanchou et al. affirmed that EGb 761 can reduce A β oligomerization and promote neurogenesis by the phosphorylation of CREB. This was evidenced by enhanced cell proliferation in the hippocampus of TgAPP/PS1 mice [141]. Overall, these studies have demonstrated that flavonoids, the primary active constituents of EGb 761, may upregulate the CREB–BDNF pathway and therefore exert neuroprotection.

Combination therapy of EGb 761 with bone-marrow-derived mesenchymal stem cells (BMSCs) has shown a synergistic effect in animals with autoimmune encephalomyelitis. The therapeutic mechanism involves the inhibition of pro-inflammatory cytokines, demyelination, and protection axons and neurons [142]. Other studies have documented that GA prevents p-Tau deposition and thus protects cells from toxicity associated with Tau hyperphosphorylation. Interestingly, the degree of dementia is closely correlated with the production of hyperphosphorylated Tau aggregates, making EGb 761 crucial to counteract the neurodegenerative process [143].

Ginkgo biloba extracts, mainly flavonoids and ginkgolides, exert inhibitory effects on acetylcholinesterase activity. In fact, cholinergic agonists can reduce inflammation by blocking inflammatory signals, particularly the ubiquitous nuclear protein HMGB1 that is released by dying cells or activated innate immunity cells to promote inflammation [144]. It has been suggested that nicotinic receptors nAChRs may control the expression of ACE2 and serve as a binding receptor for S1 protein, leading to an inflammatory response. However, EGb may counteract the central inhibitory and anti-inflammatory effects of GABAergic neurons, leading to increased cortical neuronal activity and an increased risk of convulsion [145,146]. However, meta-analysis research has proven that there is no convulsion risk associated with the anxiolytic action of EGb, which is mediated through the regulation of GABAergic neurons [147]. In patients with dementia, EGb 761[®] has shown promise in alleviating comorbid neurosensory symptoms and improving memory deficits [147].

In another study, EGb 761 showed neuroprotective effects against oxidative-stress-induced apoptotic cell death by inhibiting apoptosis in a p53-dependent pathway, preventing mitochondrial membrane damage, reducing the release of cytochrome C from the mitochondria, upregulating the anti-apoptotic protein Bcl-2, and inhibiting PARP cleavage [148]. The anti-apoptotic effects are schematically presented in Figure 5.




Figure 5. Schematic representation of the anti-apoptotic and anti-inflammatory effects of Ginkgo biloba extract (EGb) and its constituents. (1) Inhibition of ROS and suppression of the expression of pro-inflammatory mediators (e.g., COX-2 and NO) and pro-inflammatory cytokines (TNF- α , IL-6, and IL-1 β) via the NF- κ B signaling pathway. EGb can also inhibit the STAT 1/3 pathway. (2) Blocking of iNOS expression through a reduction in NO levels. (3) Inhibition of LPS-induced inflammatory response. (4) Prevention of mitochondrial oxidative stress by promoting the expression of anti-apoptotic proteins. (5) Inhibition of TLR4-NF- κ B signaling through the PI3K/Akt pathway. (6) Prevention of the intracellular accumulation of p-Tau and cellular protection from Tau-hyperphosphorylation-related toxicity. (7) Blocking signaling pathways that involve CDK5, p38 MAPK, and GSK-3 β . (8) Inhibition of NMDA and AMPA receptors, preventing the phosphorylation of c-Jun N-terminal kinase (JNK). (Created with BioRender).

The work of Wang et al. showed that EGb may be used to increase cerebral blood flow and cognitive function by co-administration with 75 mg of aspirin toward the treatment of vascular cognitive impairment of non-dementia [149]. In a randomized, double-blind exploratory study, the authors demonstrated that administration of EGb (Symfona[®] forte) at a dose of 120 mg/twice daily for at least 6 months may improve dual-task-related gait performance in patients with MCI [150]. Moreover, extensive work by Kuo et al. found that GA exhibits a strong therapeutic promise, like memantine, for treating AD by blocking NMDA and AMPA receptors. GA also suppresses c-Jun N-terminal kinase (JNK) activation at different doses (1–200 μ M) in A β -induced neuronal depolarization in mice (Figure 5) [151].

In parallel, Yu et al. demonstrated the neuroprotective effect of Ginkgo biloba dropping pills (GBDP) in the amelioration of PD [152]. In that study, the pharmacological effects of GBDP and EGb 761 were exploited in both in vivo and in vitro models of PD. Following GBDP and EGb 761 treatments, the viability of DA neurons in zebrafish was assessed via tyrosine hydroxylase immunostaining. Dopaminergic neurons in zebrafish were significantly lost after exposure to 400 μ M 6-OHDA for 48 h. Nevertheless, administration of 250 or 500 mg/mL of GBDP or 250 mg/mL of EGb 761 rescued the death of dopaminergic neurons induced with 6-OHDA. No protection was observed with further GBDP and EGb 761 dosages (Figure 6A,B). Moreover, GBDP reduced cognitive impairment and neuronal damage in MPTP-induced PD mice and reversed the effect of 6-OHDA-induced dopaminergic neuronal loss in zebrafish (Figure 6C). In vitro findings revealed that the neuroprotective effects of GBDP can be mediated through the Akt/GSK3 β pathway (Figure 6D,E) [152].




Figure 6. Representative images of dopaminergic neurons in the zebrafish brain, acquired using TH immunostaining. (A) Ginkgo biloba dropping pills (GBDP) prevented the loss of dopaminergic neurons induced by 6-OHDA. The red arrow shows dopaminergic neurons in the zebrafish brain. (B) The area of the dopaminergic neurons calculated for each group. ### $p < 0.0001$ vs. the control group; * $p < 0.05$ and ** $p < 0.001$ vs. the 6-OHDA group ($n = 10$ per group). (C) HE staining of brain sections of an MPTP-induced mouse model of Parkinson's disease. The black arrow indicates significant diminished and loose nerve fiber components, which are lightly stained, while the yellow arrow shows intensive staining of the nuclei of several atrophied cells. Glial cells exhibited modest hyperplasia, as shown by the green arrow. (D,E) In MPP-treated human SH-SY5Y cells, GBDP administration reduced the Bax/Bcl-2 ratio and elevated Akt/GSK3 β . ### $p < 0.0001$ vs. the MPP+ group. Adapted with permission from [152]. Copyright {2021} Science-HHS Public Access (PubMedCentral).

Table 3 summarizes the reported neuroprotective effects of EGb.

Table 3. In vivo and in vitro evaluation of bioactive constituents of Ginkgo biloba and their neuro-protective role under neurodegenerative conditions.

Ginkgo biloba Constituents	Neurological Condition	Model	Outcome	Ref.
EGB 761	Age-associated mitochondrial dysfunction	SAMP8 mice, oral administration	<ul style="list-style-type: none"> • Protection against mitochondrial dysfunction in platelets of young and old mice • Reduction in ROS-induced apoptosis 	[153,154]
Ginkgetin and bilobalide	PD	MPTP-induced mice, oral administration	<ul style="list-style-type: none"> • Eliminated neuroinflammation via decreasing TNF-α levels • Increased levels of BDNF in the substantia nigra pars compacta • Decreased levels of intracellular ROS and maintained mitochondrial membrane potential • Inhibited cell apoptosis via caspase-3 and Bcl2/Bax pathways • Increased tyrosine hydroxylase expression in the substantia nigra and SOD activity in the striatum • Chelated iron ions, downregulated L-ferritin, and upregulated transferrin receptor 1 	[155,156]
Ginkgo biloba extract (EGb LI 1370)	AD	SH-SY5Y cells expressing amyloid precursor protein (APP)	<ul style="list-style-type: none"> • Decreased oxidative stress • Ameliorated oxidative phosphorylation and restored Aβ-induced deficits • Improved oxygen consumption and upregulation of mitochondrial DNA 	[157]
Ginkgo biloba supplements (GBS)	PD	Rotenone-induced Swiss mice, oral administration	<ul style="list-style-type: none"> • Inhibited striatal dopaminergic neurodegeneration and α-synuclein immunoreactivity • Suppressed executioner caspase-3 and upregulated Nrf2 pathway • Decreased neurodegeneration of somata size and dendritic spine of striatal neurons 	[158]
Ginkgo biloba dropping pill (GBDP)	PD	In vivo: 6-OHDA-induced zebrafish MPTP-induced male C57BL/6 mice, oral administration In vitro: MPP+-induced SH-SY5Y cells	<ul style="list-style-type: none"> • Protection of dopaminergic neurons against 6-OHDA and MPTP-induced neurotoxicity mediated by the Akt/GSK3β signaling pathway • Reduced cognitive impairments and neuronal damage 	[152]
Ginkgo biloba tablets	Vascular cognitive impairment of non-dementia (VCIND)	Randomized clinical study of 80 patients with VCIND	<ul style="list-style-type: none"> • Significant improvement in the Montreal Cognitive Assessment (MoCA) score • Increased blood flow velocity of the anterior cerebral artery 	[159]
EGb (Symfona® forte 120 mg)	Mild cognitive impairment (MCI)	Randomized, double-blind, placebo exploratory study in 50–85-year-old patients with MCI and associated dual-task-related gait impairment	<ul style="list-style-type: none"> • Increased dual-task-related performance in the intervention group • EGb-associated numerical non-significant trends found after 6 months for dual-task-related gait velocity and stride time variability 	[150]

Table 3. Cont.

Ginkgo biloba Constituents	Neurological Condition	Model	Outcome	Ref.
EGb 761	Huntington's disease	3-NP-induced rats, I.P. injection	<ul style="list-style-type: none"> Downregulation of striatal Bax Upregulation of striatal Bcl-xl expression level 	[105,160]
Kaempferol and luteolin	AD	Transgenic drosophila expressing wild-type human A β 42	<ul style="list-style-type: none"> Improved memory Reduced oxidative stress and acetylcholinesterase activity Inhibition of Aβ42 plaque formation after binding to Aβ42 Inhibition of AChE Increased GHS content 	[137,161]
Bilobalide	Cerebral ischemia and reperfusion (I/R) injury	MCAO male Sprague–Dawley rats	<ul style="list-style-type: none"> Significantly decreased infarct volume, brain edema, MDA, nitric oxide, TNF-α, and IL-1β Increased SOD activity Downregulated p-JNK1/2 and p-p38 MAPK expression 	[162]
Isorhamnetin	Ischemia-induced cerebral vascular degeneration	Human brain microvascular endothelial cells (HBMECs)	<ul style="list-style-type: none"> Reduced activation of the extrinsic apoptotic pathway by decreasing caspase-3 and caspase-8 Inhibition of FAS/FASL expression and suppressed NF-κB nuclear translocation 	[163]
EGb 761	Ischemic brain injury	MCAO male Sprague–Dawley rats	<ul style="list-style-type: none"> Decreased parvalbumin expression 	[164]
Ginkgolide B (GB)	Vascular dementia (VD), hypoxic injury	In vivo: BCCAO rats, intraperitoneal injection In vitro: Oxygen-glucose deprivation (OGD) in SH-SY5Y cells, primary hippocampal neurons subjected to chemical hypoxia (0.7 mM CoCl ₂)	<ul style="list-style-type: none"> Reduced TLR4/NF-κB-mediated neuroinflammation Regulated Ca²⁺ influx and homeostasis Decreased number of apoptotic cells in different areas of the hippocampus Improved antioxidant defense system (SOD, GSH, CAT) Decreased concentration of malondialdehyde (MDA) in the rat hippocampus 	[165–167]

3.3. Bioavailability and Safety of EGb

Acute toxicity studies have shown that EGb has a lethal dose (LD50) of 1.1 g/kg, 1.9 g/kg, and 7.73 g/kg in mice and 1.1 g/kg, 2.1 g/kg, and >10 g/kg in rats when administered intravenously, intraperitoneally, and orally, respectively [168,169]. In the older population, EGb is frequently used in the management of type 2 diabetes (T2DM), hypertension, or rheumatism. However, the interaction of EGb with other drug candidates can lead to bleeding. In a retrospective case series study, a 73-year-old man who had been taking 75 mg of a ginkgo supplement for 6 months as an aid to improve his memory deficits experienced episodes of spontaneous bleeding. The supplement included 27% ginkgo flavone glycosides and 10% terpene lactones [170]. A case report revealed that a 38-year-old lady who had been taking thiamine and Ginkgo biloba extract (240 mg/day) for 4 years experienced a brain hemorrhage [171]. Another study documented the case of a 70-year-old man with spontaneous iris bleeding (hyphema). This clinical occurrence took place 1 week after the patient started taking Ginkoba, a different natural Ginkgo biloba supplement (40 mg twice a day), in combination with 325 mg of aspirin every day. Ginkoba was withdrawn from therapy after monitoring the case for 3 months, and no further bleeding incidents were observed. Thus, it was proposed that the bleeding was caused by interactions between aspirin and ginkgo biloba extracts [172].

From the examples cited, research connecting Ginkgo biloba therapy with bleeding risk includes case reports. In addition, comprehensive analyses of randomized controlled studies have not identified any elevated risk of bleeding in patients using Ginkgo biloba extracts [173,174]. For example, in a prospective, double-blind, randomized, placebo-controlled trial, the administration of EGb 761 to young, healthy male volunteers at three different doses (120, 240, and 480 mg/day) had no effect on platelet function or coagulation [175]. Moreover, it has been reported that EGb 761 at a dosage of 120 mg/day inhibits platelet aggregation and thromboxane B2 synthesis [176]. In general, there is inconclusive evidence that Ginkgo biloba extracts are associated with bleeding. However, further research is necessary to resolve these controversies.

4. Perspectives for Use of Ginkgo Biloba in Nanotherapies of Neurological Disorders

Although preclinical studies of antioxidants to improve neuronal dysfunction have shown encouraging results, the outcomes of clinical trials have not always been conclusive. In general, antioxidant compounds have mainly suppressed clinical symptoms but are unable to halt or reverse disease progression [177]. In the absence of delivery systems, Ginkgo biloba (120 mg daily dosage) did not improve patient performance in neuropsychological tests of memory, attention, or speech during a 6-week, placebo-controlled, double-blind clinical study including 219 individuals [178]. Similarly, a feasibility investigation by Dodge et al. reported no difference in episodic memory deterioration in patients who received 240 mg/day of Ginkgo biloba or a placebo during an average follow-up period of 3.5 years [179]. The clinical translation of free antioxidant drugs may be hampered by several issues related to drug delivery efficacy. These problems include low drug bioavailability, low permeability through the CNS, limited half-life, and toxicity [180] (Figure 7). Significant efforts have been made to increase the clinical efficacy of both natural and synthetic antioxidants by using drug delivery systems to overcome their drawbacks. For example, investigations of drug conjugates, complexes, and nanocarriers of various polymeric materials have been performed [181–183].




Figure 7. Advantages of nanotherapies over conventional formulations [183–185].

4.1. Intranasal Administration and Biodistribution of Nanoparticulate Carriers

Delivering nanomedicines to the brain to treat CNS disorders is a major advantage of circumventing the BBB and reducing systemic exposure. Intranasal administration has attracted attention as a potential delivery mechanism to the brain for neuroprotection. The intranasal delivery method has been proposed for the treatment of CNS disorders (e.g., migraine, sleep disorders, brain tumors, multiple sclerosis, PD, and AD), thanks to its non-invasiveness and high patient compliance [184,186–188]. Because the olfactory mucosa is in direct contact with the CNS, intranasal delivery of small and large molecules can successfully target the brain. This prevents the accumulation of drug molecules in vital

organs, such as the liver, spleen, and kidney, which would lessen systemic adverse effects. Alternative delivery routes are via the lymphatic and vascular systems [189,190].

Nanotechnology has considerable potential for delivering therapeutic compounds to the brain through different mechanisms that allow blood–brain barrier passage. Nanoparticles (NPs) can improve drug solubility, increase the residence time of the active compounds at the target site, enhance their mucosal permeation and cellular internalization, regulate the release of encapsulated drugs, and lessen systemic side effects by limiting the distribution to non-targeted areas [189].

Wen et al. proposed nasal nanotherapy targeted to the brain with decreased immunogenicity with a drug delivery system. PEG–PLGA nanoparticles were modified with conventional lectin by combining a synthetic OL–conjugate PEG–PLGA (OL–PEG–PLGA) with PEG–PLGA [191]. For nanotherapy, odorranalectin (OL)-modified NPs were fabricated via the double-emulsion technique. A hemagglutination test was conducted to validate the biorecognitive activity of OL on the surface of the NPs. The results in Figure 8 show that OL-conjugated NPs possess hemagglutinating activity and demonstrate improved bioactivity. The nose-to-brain transport properties of the OL-conjugated NPs were examined using an in vivo fluorescent imaging approach with DiR dye as a tracer. The nanocarriers were co-administered with urocortin peptide via the intranasal route. The therapeutic efficacy of hemiparkinsonian rats was assessed using a rotation behavior test, a tyrosine hydroxylase test, and a neurotransmitter determination test. The obtained data suggested that the intranasal delivery of functionalized NPs to the brain enhances the therapeutic efficacy of nanodrugs in PD models [191].




Figure 8. Delivery of odorranalectin (OL)-conjugated NPs to the brain monitored with an in vivo imaging system. (A) Fluorescence images of the upper half-body of the mouse overlaid on X-ray images, following intranasal administration of DiR-labeled NPs and OL-conjugated NPs at different time points. (B) Semi-quantitative results of the fluorescence intensity in the brain region. * $p < 0.05$, significantly different. (C) Fluorescence images of major organs overlaid on white-light images at 8 h after intranasal administration of DiR-loaded NPs and OL-conjugated NPs to mice. Copyright © 2011 Elsevier B.V. All rights reserved, with permission from Elsevier [191].

4.2. Ginkgo-Biloba-Based Nanotherapy for Neuroprotection and Regeneration from SARS-CoV-2 Neurological Damage

In a recent study, Ginkgo-biloba-extract-loaded chitosan nanoparticles (Gb–CsNPs) were synthesized via an ionic gelation method. The outcomes revealed that the average size of the Gb–CsNPs was 104.4 nm, with a zeta potential of 29.3 mV and a polydispersity index (PDI) of 0.09. The encapsulation efficacy and drug-loading capacity were 40% and 97.4%, respectively. The neuroprotective efficacy of the Gb–CsNPs was examined in an oxidative-stress-induced cellular model (SH-SY5Y). The results showed increased cell survival from 60% to 92.3%, proving the NPs' efficacy and biocompatibility [192]. Additionally, the encapsulation of EGb in chitosan NPs improved its neuroprotective properties [192].

Wang et al. developed Ginkgo biloba extract nanoparticles to enhance the oral bioavailability of GBE in Sprague–Dawley rats at a dosage of 40 mg kg^{−1}. The C_{max} value of the flavonoids in raw GBE and GBE nanoparticles was reported to be 2.949 lg mL^{−1} at 0.5 h and 4.302 lg mL^{−1} in 0.333 h, respectively [193]. In a separate study, Zhao et al. demonstrated the ability of GBE NPs to transport across barriers, including the chorion, the GI barrier, the BRB, and the BBB. GBE was encapsulated by using poly(ethylene glycol)-co-poly(ε-caprolactone) (PEG–PCL) nanoparticles. The developed nanoparticles facilitated the sustained release and enhanced brain uptake of GBE in the plasma of treated animals to treat PD [194].

Additionally, the delivery of quercetin across the BBB was achieved by using SLNs via intravenous administration to improve the therapeutic efficacy of this molecule [195]. The high-pressure homogenization procedure was used to successfully formulate SLNs loaded with Ginkgo biloba extract. The SLNs exhibited an appropriate particle size and shape, sustained the release profile, and improved the loading efficiency of the active substance [196].

In contrast, Xu et al. used an aqueous extract of Ginkgo biloba leaves to synthesize AgNPs with a mean particle size of 40.2 ± 1.2 nm, a polydispersity index of 0.091 ± 0.011, and a zeta potential of −34.56 mV [197]. In vitro results showed that EGb–AgNP treatment significantly increases intracellular ROS levels, facilitates cytochrome C release from the mitochondria into the cytosol, and facilitates caspase-9 and caspase-3 cleavage. This indicated that EGb–AgNPs can induce the activation of caspase-dependent mitochondrial apoptotic pathways, which are significant for various therapeutic applications [197].

As a potential nanotherapy for Parkinson's disease (PD), Wang et al. synthesized biodegradable poly(ethylene glycol)-b-poly(trimethylene carbonate) nanoparticles (PPNPs) to deliver ginkgolide B. This enhanced the accumulation of bioactive molecules in the blood and brain [198]. The fabricated GB–PPNPs effectively promoted the sustained release of ginkgolide B for 48 h. Moreover, the GB–PPNPs at various concentrations (50, 100, 200, and 400 µg/mL) prevented the neurotoxicity induced by MPP⁺ and protected zebrafish embryos or larvae, while decreasing the level of MDA protein expression in GB–PPNP-treated mice compared to MPTP-treated mice (Figure 9). Further research revealed that mice treated with GB–PPNPs had higher levels of SOD and GSH-Px than mice treated with MPTP. Additionally, GB–PPNPs elevated the concentration of DOPAC (10.66 ± 1.12, 1.65 ± 0.18 µg/g) and HVA (5.17 ± 0.60 µg/g). These values were significantly higher than those observed in the disease group [198].




Figure 9. In vivo toxicity analysis of ginkgolide-B-loaded GB-PPNPs in zebrafish embryo and MPTP-induced murine model of PD. (A) Zebrafish embryos were treated with different concentrations of GB-PPNPs (50, 100, 200, and 400 µg/mL), and at 96 hpf, the embryo morphology was visualized via microscopy. The survival rates, hatching rates, heart rates, and zebrafish body length were calculated. Scale bar: 500 µm. (C–H) Impact of GB-PPNPs on the striatum with determined levels of (A) MDA, (B) SOD, (C) GSH-Px (means ± SD, $n = 4$), (D) dopamine, (E) DOPAC, and (F) HVA ($n = 7$). * $p < 0.05$ and ** $p < 0.01$ correspond to different treatments vs. MPTP. # $p < 0.05$ and ## $p < 0.01$ correspond to GB-PPNPs vs. GB. Adapted with permission from [198]. Copyright (2022) Science-HHS Public Access (PubMedCentral).

4.3. Green Synthesis of Ginkgo Biloba nanoEGb

Ginkgo biloba is synthesized as nanoEGb using a variety of nanocarriers, such as liposomes, polymers, cyclodextrins, micelles, and carbon-based nanoconjugates, to address its limited water solubility and poor bioavailability and improve its half-life and retention time (Table 4) [199]. The poor bioavailability of EGb has been associated with the presence of diterpenoid molecules, particularly in ginkgolides A, B, and C [199]. The biosynthesis of Ginkgo biloba leaves has been realized using gold nanoparticles (AuNPs), Fe₃O₄ magnetic nanoparticles (MNPs), and silver nanoparticles (AgNPs) [197,200,201]. This technique was demonstrated by Elshazly et al., who developed AgNPs using Ginkgo biloba extract. The nanoparticles exhibited a mean particle size ranging from 5.46 to 19.40 nm and an average diameter of 11.81 nm. In vitro experiments demonstrated that AgNPs have a moderate inhibition against MERS-CoV and HCoV-229E, which share similar sequence homology with SARS-CoV-2 [202]. Figure 10 demonstrates the potential uptake mechanism of an EGb nano-conjugate via transcytosis.

Table 4. Preparation, characterization, and evaluation of active constituents of Ginkgo-biloba-based nanoparticles for treatment of neurological damages linked to COVID-19.

Molecule	Nanocarrier	Technique	ζ -Potential, mV	Size, nm	PDI	DL%	EE%	Morphology	Pathology	Ref.
Ginkgolide B	GB-PPNPs	Antisolvent precipitation	-10.37 ± 0.56	77.58 ± 0.77	0.124 ± 0.018	19.43%	92.08	Spherical	PD	[198]
Quercetin	QNPs	Antisolvent precipitation	—	<1000	0.734	—	—	—	AD	[203]
Quercetin	QT-SPION conjugates	Co-precipitation technique	—	30–50	—	—	—	Spherical	AD	[204]
Ginkgo biloba extract	Egb niosomes	Freeze-drying and spray-drying methods	Noisome suspension, -0.1 ± 1.7 Freeze-drying, -11.6 ± 4.3 Spray-drying, -33.6 ± 1.6	141.3 ± 11.9 661.3 ± 78.6 680.2 ± 90.0	—	—	50.0 ± 1.9 50.1 ± 1.0 77.5 ± 1.0	Spherical and smooth surface	Improving oral bioavailability	[205]
Kaempferol	Kaempferol-loaded nanoparticles (KFP-NPs)	Quasi-emulsion methods	-28.5 to -7.5	201 ± 0.45	0.12 to 0.95	11.34 to 15.06	30.14 to 46.72	Solid sphere with a smooth surface	Hepatoprotective and antioxidant effects	[206]
Luteolin	Luteolin-loaded chitosomes (LUT-CHS)	Ethanol injection	37.4 ± 2.13	412.8 ± 3.28	0.378 ± 0.07	—	86.6 ± 2.05	Spherical vesicular system with a phospholipid bilayer membrane	Cognitive dysfunction in Alzheimer's disease (AD)	[207]
Ginkgo biloba	Egb-loaded solid lipid nanoparticles (SLNs)	High-pressure homogenization	-12.6 to -28	104 to 621	< 0.5	—	79 to 89	Spherical, smooth, and rounded surface	Cytotoxicity and antibacterial activities	[196]
Isorhamnetin	Isorhamnetin-PLGA NPs	Double-emulsion solvent evaporation	—	255 to 342	—	—	—	—	—	[208]

Table 4. Cont.

Ginkgo biloba extract	Gb-extract-loaded chitosan nanoparticles (Gb-CsNPs)	Ionic gelation	29.3	104.4	0.09	40	97.4	Smooth and spherical morphology	Oxidative stress	[192]
	Silver nanoparticles (AgNPs)	Biogenic synthesis	-74.2 ± 2.45	5.46 to 19.40	—	—	—	Agglomerated spherical shapes	Antiviral activities against MERS-CoV and HCoV-229E	[202]
	Self-emulsifying drug delivery systems (SEEDS)	Self-emulsification	—	~100	—	—	—	—	Improving oral absorption	[209]
	EGB-loaded nanospheres	Nanoprecipitation	—	100 to 200	0.428 to 0.478	—	—	Oval or spherical shape with a smooth surface	In vitro release kinetics	[210]




Figure 10. Antioxidant-based nanotherapy via green synthesis of nanoparticles. The scheme illustrates the benefits of delivering Ginkgo biloba biogenic metallic NPs to increase their half-life, capacity to penetrate the BBB, bioavailability, and sustained effect, thus neutralizing oxidative stress in neurological disorders (created with BioRender).

4.4. Characterization Techniques for Nanotherapeutics

For the development of nanotherapeutics, nanoparticles are characterized using different techniques [198–213]. Sufficient knowledge of the safety, efficacy, and quality of nanotherapeutics is required to enable easy translation toward clinical applications [211]. Various techniques are used to characterize the size, charge, morphology, drug encapsulation efficiency, drug loading, toxicity, etc., including dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), UV–VIS spectrometry, transmission electron microscopy (TEM), scanning electron microscopy (SEM), and cytotoxicity assessment via (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays (Table 5) [212,213].

Table 5. Nanospecific characteristics and physico-chemical properties of drug-loaded nanoparticles, which are considered relevant for the preclinical characterization of nanomedicines/nanotherapeutics formulated in aqueous media.

Nanospecific Characteristics	Test Method
Size/size distribution	DLS
Physical form/shape/morphology	TEM, cryo-TEM
Surface charge	Zeta potential, electrophoretic mobility (EPM)
Aggregation behaviour	DLS

Table 5. Cont.

Nanospecific Characteristics	Test Method
Stability and uniformity	DLS, UV–VIS spectroscopy
Density/weight/volume fraction of nanomaterial dispersed in the medium	Ultracentrifugation, densitometry
Drug encapsulation	UV–VIS spectrometry, high-performance liquid chromatography (HPLC)
Presence of targeting moieties	Kinetic turbidity assays, Spectroscopic assays (UV–VIS, circular dichroism), surface plasmon resonance (SPR) binding assays
Toxicity	Cytotoxicity assessment using MTT and LDH assays
Biocompatibility	Immunological response, hemolytic properties
Structural and functional properties	TEM, SEM, small-angle X-ray scattering (SAXS), NTA, high-resolution transmission electron microscopy (HRTEM), atomic force microscopy (AFM), extended X-ray absorption fine structure (EXAFS), ferromagnetic resonance (FMR), DSC, differential centrifugal sedimentation (DCS), inductively coupled plasma atomic emission spectroscopy (ICP-MS), UV–VIS, matrix-assisted laser desorption/ionization (MALDI), nuclear magnetic resonance (NMR), superparamagnetic relaxometry, tunable resistive pulse sensing (TRPS)

5. Conclusions

It is indispensable to continue studying the mechanisms that underlie the pathophysiological process of SARS-CoV-2 infection. This will enable researchers to uncover the therapeutic targets that may be used for their management. According to this review, it may be suggested that Ginkgo biloba has potential positive effects, including anxiolytic, antineurotoxic, anti-inflammatory and anti-apoptotic functions, and has been explored in treating neurological disorders, particularly AD, PD, and dementia. Nevertheless, further studies are needed to corroborate the activity and mechanisms of action of this phytochemical since it could constitute an alternative for the treatment of vascular and degenerative diseases. Nanotechnology-based drug delivery systems could be an approach to address the limitations of antioxidant compounds, which include insufficient dosing, limited bioavailability, restricted transport to the CNS, transient retention, and low antioxidant capacity to completely scavenge the effect of ROS. The development of experimental techniques to mimic ROS has made it possible to study oxidative stress in the CNS. These methods will be fundamental for future discoveries related to the role of oxidative stress in neurological diseases.

Author Contributions: Writing—original draft preparation, T.A.; visualization, T.A.; writing—review and editing, A.A. and T.A.; supervision, A.A. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The authors confirm that the data supporting the findings of this study are available within the article.

Acknowledgments: Figures 2, 3, 5 and 10 were generated with BioRender.com (accessed on 6 November 2022). T.A. acknowledges a PhD fellowship from Campus France, and A.A. acknowledges membership in the CNRS GDR2088 BIOMIM research network.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

3-NP—3-nitropropionic acid; 6-OHDA—6-hydroxydopamine; 8-OHG—8 hydroxyguanosine; ACE2—angiotensin-converting enzyme 2; AKT—protein kinase B; ALI—acute lung injury; ALS—amyotrophic lateral sclerosis; AMPA— α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; ARE—antioxidant response element; AT1R—angiotensin II receptor type 1; A β —amyloid beta; BBB—blood–brain barrier; BCL2—B-cell lymphoma-2; B-CSF—blood–cerebrospinal fluid; BDNF—brain-derived neurotrophic factor; cAMP—cyclic adenosine monophosphate; CAT—catalase; CDK5—cyclin-dependent kinase 5; CNS—central nervous system; COX2—cyclooxygenase-2; CREB—cAMP-response-element-binding protein; CVO—circumventricular organ; DCN—dopaminergic neuron; ECT—electron transport chain; EGb—Ginkgo biloba extract; EGCG—epigallocatechin gallate; eNOS—endothelial nitric oxide synthase; ER—endoplasmic reticulum; ERK—extracellular-signal-regulated kinase; FOXO3—forkhead box O3; GA—ginkgolide A; GCLC—glutamate-cysteine ligase catalytic subunit; GCLM—glutamate cysteine ligase modifier; GPx—glutathione peroxidase; GSH—glutathione; GSK-3 β —glycogen synthase kinase-3 beta; hBMVEC—human brain microvascular endothelial cell; HIF-1—hypoxia inducible factor 1; HMOX1—heme oxygenase 1; hNPC—human neural progenitor cell; HO-1—*heme oxygenase*; I-K β —Ikappa B kinase; IL-1 β —interleukin 1 beta; JNK—c-Jun N-terminal kinase; LPS—lipopolysaccharide; LRRK2—leucine-rich repeat kinase 2; MAM—mitochondria-associated endoplasmic reticulum membrane; MAPK—mitogen-activated protein kinase; MAPT—microtubule-associated protein tau; MCAO—middle cerebral artery occlusion; MDA—malondialdehyde; MERS-CoV—Middle East respiratory syndrome coronavirus; MPO—myeloperoxidase; MRI—magnetic resonance imaging; MtK_{ATP}—ATP-sensitive potassium channels of the inner mitochondrial membrane; mtROS—mitochondrial reactive oxygen species; mTOR—mechanistic target of rapamycin; MTPT—1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MYD88—myeloid differentiation primary response 88; nAChR—nicotinic acetylcholine receptor; NADPH—nicotinamide adenine dinucleotide phosphate; NF- κ B—nuclear factor kappa B; NLRP3—NOD-like receptor proteins 3; NMDA—N-methyl-D-aspartic acid; NOX—NADPH oxidase; NQO1—NAD(P)H quinone dehydrogenase 1; Nrf2—nuclear factor erythroid 2-related factor 2; PARP—poly (ADP-ribose) polymerase; PD—Parkinson’s disease; PGC-1 α —peroxisome proliferator activated receptor gamma coactivator 1 alpha; PI3K—phosphoinositide 3-kinase; PINK1—PTEN-induced kinase 1; PKB—protein kinase B; PRDX3—peroxiredoxin 3; PSEN1—presenilin 1; PTEN—phosphatase and tensin homolog; RBD—receptor-binding domain; ROS—reactive oxygen species; SARS-CoV-2—severe acute respiratory syndrome coronavirus 2; SOD2—superoxide dismutase 2; STAT3—signal transducer and activator of transcription 3; TLR4—toll-like receptor 4; TNF- α —tumor necrosis factor alpha; TXA2—thromboxane A2; γ GCS—gamma glutamylcysteine synthetase; $\Delta\Psi$ m—mitochondrial membrane potential

References

1. Raveendran, A.V.; Jayadevan, R.; Sashidharan, S. Long COVID: An Overview. *Diabetes Metab. Syndr. Clin. Res. Rev.* **2021**, *15*, 869–875. [[CrossRef](#)] [[PubMed](#)]
2. Wiczfinska, J.; Kleniewska, P.; Pawliczak, R. Oxidative Stress-Related Mechanisms in SARS-CoV-2 Infections. *Oxidative Med. Cell. Longev.* **2022**, *2022*, 5589089. [[CrossRef](#)] [[PubMed](#)]
3. Kase, Y.; Okano, H. Neurological Pathogenesis of SARS-CoV-2 (COVID-19): From Virological Features to Clinical Symptoms. *Inflamm. Regen.* **2021**, *41*, 15. [[CrossRef](#)] [[PubMed](#)]
4. Nuzzo, D.; Picone, P. Potential Neurological Effects of Severe COVID-19 Infection. *Neurosci. Res.* **2020**, *158*, 1–5. [[CrossRef](#)] [[PubMed](#)]
5. Edinoff, A.N.; Chappidi, M.; Alpaugh, E.S.; Turbeville, B.C.; Falgoust, E.P.; Cornett, E.M.; Murnane, K.S.; Kaye, A.M.; Kaye, A.D. Neurological and Psychiatric Symptoms of COVID-19: A Narrative Review. *Psychiatry Int.* **2022**, *3*, 158–168. [[CrossRef](#)]
6. Sykes, D.L.; Holdsworth, L.; Jawad, N.; Gunasekera, P.; Morice, A.H.; Crooks, M.G. Post-COVID-19 Symptom Burden: What Is Long-COVID and How Should We Manage It? *Lung* **2021**, *199*, 113–119. [[CrossRef](#)]
7. Ahamed, J.; Laurence, J. Long COVID Endotheliopathy: Hypothesized Mechanisms and Potential Therapeutic Approaches. *J. Clin. Investig.* **2022**, *132*, e161167. [[CrossRef](#)]
8. Carfi, A.; Bernabei, R.; Landi, F.; for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA* **2020**, *324*, 603. [[CrossRef](#)]
9. Pilotto, A.; Cristillo, V.; Cotti Piccinelli, S.; Zoppi, N.; Bonzi, G.; Sattin, D.; Schiavolin, S.; Raggi, A.; Canale, A.; Gipponi, S.; et al. Long-Term Neurological Manifestations of COVID-19: Prevalence and Predictive Factors. *Neurol. Sci.* **2021**, *42*, 4903–4907. [[CrossRef](#)]

10. Xu, Z.; Shi, L.; Wang, Y.; Zhang, J.; Huang, L.; Zhang, C.; Liu, S.; Zhao, P.; Liu, H.; Zhu, L.; et al. Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. *Lancet Respir. Med.* **2020**, *8*, 420–422. [[CrossRef](#)]
11. Rass, V.; Beer, R.; Schiefecker, A.J.; Lindner, A.; Kofler, M.; Ianosi, B.A.; Mahlknecht, P.; Heim, B.; Peball, M.; Carbone, F.; et al. Neurological Outcomes 1 Year after COVID-19 Diagnosis: A Prospective Longitudinal Cohort Study. *Euro. J. Neurol.* **2022**, *29*, 1685–1696. [[CrossRef](#)]
12. Vollbracht, C.; Kraft, K. Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C. *Front. Pharmacol.* **2022**, *13*, 899198. [[CrossRef](#)] [[PubMed](#)]
13. Gheblawi, M.; Wang, K.; Viveiros, A.; Nguyen, Q.; Zhong, J.-C.; Turner, A.J.; Raizada, M.K.; Grant, M.B.; Oudit, G.Y. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. *Circ. Res.* **2020**, *126*, 1456–1474. [[CrossRef](#)]
14. Villa, C.; Rivellini, E.; Lavitrano, M.; Combi, R. Can SARS-CoV-2 Infection Exacerbate Alzheimer’s Disease? An Overview of Shared Risk Factors and Pathogenetic Mechanisms. *JPM* **2022**, *12*, 29. [[CrossRef](#)] [[PubMed](#)]
15. Domingues, R.B.; Mendes-Correa, M.C.; de Moura Leite, F.B.V.; Sabino, E.C.; Salarini, D.Z.; Claro, I.; Santos, D.W.; de Jesus, J.G.; Ferreira, N.E.; Romano, C.M.; et al. First Case of SARS-COV-2 Sequencing in Cerebrospinal Fluid of a Patient with Suspected Demyelinating Disease. *J. Neurol.* **2020**, *267*, 3154–3156. [[CrossRef](#)] [[PubMed](#)]
16. Bonaventura, A.; Vecchié, A.; Dagna, L.; Martinod, K.; Dixon, D.L.; Van Tassell, B.W.; Dentali, F.; Montecucco, F.; Massberg, S.; Levi, M.; et al. Endothelial Dysfunction and Immunothrombosis as Key Pathogenic Mechanisms in COVID-19. *Nat. Rev. Immunol.* **2021**, *21*, 319–329. [[CrossRef](#)]
17. Lage, S.L.; Amaral, E.P.; Hilligan, K.L.; Laidlaw, E.; Rupert, A.; Namasivayan, S.; Rocco, J.; Galindo, F.; Kellogg, A.; Kumar, P.; et al. Persistent Oxidative Stress and Inflammasome Activation in CD14^{high}CD16⁺ Monocytes From COVID-19 Patients. *Front. Immunol.* **2022**, *12*, 799558. [[CrossRef](#)]
18. Blesa, J.; Trigo-Damas, I.; Quiroga-Varela, A.; Jackson-Lewis, V.R. Oxidative Stress and Parkinson’s Disease. *Front. Neuroanat.* **2015**, *9*, 91. [[CrossRef](#)]
19. Xiong, Y.; Zhu, G.-H.; Wang, H.-N.; Hu, Q.; Chen, L.-L.; Guan, X.-Q.; Li, H.-L.; Chen, H.-Z.; Tang, H.; Ge, G.-B. Discovery of Naturally Occurring Inhibitors against SARS-CoV-2 3CLpro from Ginkgo Biloba Leaves via Large-Scale Screening. *Fitoterapia* **2021**, *152*, 104909. [[CrossRef](#)]
20. Chen, Z.; Cui, Q.; Cooper, L.; Zhang, P.; Lee, H.; Chen, Z.; Wang, Y.; Liu, X.; Rong, L.; Du, R. Ginkgolic Acid and Anacardic Acid Are Specific Covalent Inhibitors of SARS-CoV-2 Cysteine Proteases. *Cell Biosci.* **2021**, *11*, 45. [[CrossRef](#)]
21. Noor-E-Tabassum; Das, R.; Lami, M.S.; Chakraborty, A.J.; Mitra, S.; Tallei, T.E.; Idroes, R.; Mohamed, A.A.-R.; Hossain, M.J.; Dhama, K.; et al. Ginkgo Biloba: A Treasure of Functional Phytochemicals with Multimedicinal Applications. *Evid. Based Complement. Altern. Med.* **2022**, *2022*, 8288818. [[CrossRef](#)] [[PubMed](#)]
22. Sochocka, M.; Ochnik, M.; Sobczyński, M.; Gębura, K.; Zambrowicz, A.; Naporowski, P.; Leszek, J. Ginkgo Biloba Leaf Extract Improves an Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer’s Disease Patients. *Nutrients* **2022**, *14*, 2022. [[CrossRef](#)] [[PubMed](#)]
23. Barbalho, S.M.; Direito, R.; Laurindo, L.F.; Marton, L.T.; Guiguer, E.L.; Goulart, R.D.A.; Tofano, R.J.; Carvalho, A.C.A.; Flato, U.A.P.; Capelluppi Tofano, V.A.; et al. Ginkgo Biloba in the Aging Process: A Narrative Review. *Antioxidants* **2022**, *11*, 525. [[CrossRef](#)] [[PubMed](#)]
24. Tomino, C.; Ilari, S.; Solfrizzi, V.; Malafoglia, V.; Zilio, G.; Russo, P.; Proietti, S.; Marcolongo, F.; Scapagnini, G.; Muscoli, C.; et al. Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo Biloba (EGb 761[®]). *Pharmaceutics* **2021**, *14*, 305. [[CrossRef](#)] [[PubMed](#)]
25. Singh, S.K.; Srivastav, S.; Castellani, R.J.; Plascencia-Villa, G.; Perry, G. Neuroprotective and Antioxidant Effect of Ginkgo Biloba Extract Against AD and Other Neurological Disorders. *Neurotherapeutics* **2019**, *16*, 666–674. [[CrossRef](#)]
26. Al-kuraishy, H.M.; Al-Gareeb, A.I.; Kaushik, A.; Kujawska, M.; Batiha, G.E. *Ginkgo Biloba* in the Management of the COVID-19 Severity. *Arch. Pharm.* **2022**, *355*, 2200188. [[CrossRef](#)]
27. Baig, A.M. Deleterious Outcomes in Long-Hauler COVID-19: The Effects of SARS-CoV-2 on the CNS in Chronic COVID Syndrome. *ACS Chem. Neurosci.* **2020**, *11*, 4017–4020. [[CrossRef](#)]
28. Zhou, L.; Zhang, M.; Wang, J.; Gao, J. Sars-Cov-2: Underestimated Damage to Nervous System. *Travel Med. Infect. Dis.* **2020**, *36*, 101642. [[CrossRef](#)]
29. Grifoni, A.; Sidney, J.; Zhang, Y.; Scheuermann, R.H.; Peters, B.; Sette, A. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. *Cell Host Microbe* **2020**, *27*, 671–680.e2. [[CrossRef](#)]
30. Arbour, N.; Côté, G.; Lachance, C.; Tardieu, M.; Cashman, N.R.; Talbot, P.J. Acute and Persistent Infection of Human Neural Cell Lines by Human Coronavirus OC43. *J. Virol.* **1999**, *73*, 3338–3350. [[CrossRef](#)]
31. Collins, A.R.; Sorensen, O. Regulation of Viral Persistence in Human Glioblastoma and Rhabdomyosarcoma Cells Infected with Coronavirus OC43. *Microb. Pathog.* **1986**, *1*, 573–582. [[CrossRef](#)] [[PubMed](#)]
32. Chaná-Cuevas, P.; Salles-Gándara, P.; Rojas-Fernandez, A.; Salinas-Rebolledo, C.; Milán-Solé, A. The Potential Role of SARS-COV-2 in the Pathogenesis of Parkinson’s Disease. *Front. Neurol.* **2020**, *11*, 1044. [[CrossRef](#)] [[PubMed](#)]
33. Boroujeni, M.E.; Simani, L.; Bluysen, H.A.R.; Samadikhah, H.R.; Zamanlui Benisi, S.; Hassani, S.; Akbari Dilmaghani, N.; Fathi, M.; Vakili, K.; Mahmoudiasl, G.-R.; et al. Inflammatory Response Leads to Neuronal Death in Human Post-Mortem Cerebral Cortex in Patients with COVID-19. *ACS Chem. Neurosci.* **2021**, *12*, 2143–2150. [[CrossRef](#)] [[PubMed](#)]

34. Palpagama, T.H.; Waldvogel, H.J.; Faull, R.L.M.; Kwakowsky, A. The Role of Microglia and Astrocytes in Huntington's Disease. *Front. Mol. Neurosci.* **2019**, *12*, 258. [[CrossRef](#)] [[PubMed](#)]
35. Wu, Y.; Xu, X.; Chen, Z.; Duan, J.; Hashimoto, K.; Yang, L.; Liu, C.; Yang, C. Nervous System Involvement after Infection with COVID-19 and Other Coronaviruses. *Brain Behav. Immun.* **2020**, *87*, 18–22. [[CrossRef](#)] [[PubMed](#)]
36. Li, Y.; Bai, W.; Hashikawa, T. Response to Commentary on "The Neuroinvasive Potential of SARS-CoV-2 May Play a Role in the Respiratory Failure of COVID-19 Patients". *J. Med. Virol.* **2020**, *92*, 707–709. [[CrossRef](#)]
37. Devaux, C.A.; Lagier, J.-C.; Raoult, D. New Insights Into the Physiopathology of COVID-19: SARS-CoV-2-Associated Gastrointestinal Illness. *Front. Med.* **2021**, *8*, 640073. [[CrossRef](#)]
38. Qian, Q.; Fan, L.; Liu, W.; Li, J.; Yue, J.; Wang, M.; Ke, X.; Yin, Y.; Chen, Q.; Jiang, C. Direct Evidence of Active SARS-CoV-2 Replication in the Intestine. *Clin. Infect. Dis.* **2021**, *73*, 361–366. [[CrossRef](#)]
39. Lehmann, M.; Allers, K.; Heldt, C.; Meinhardt, J.; Schmidt, F.; Rodriguez-Sillke, Y.; Kunkel, D.; Schumann, M.; Böttcher, C.; Stahl-Hennig, C.; et al. Human Small Intestinal Infection by SARS-CoV-2 Is Characterized by a Mucosal Infiltration with Activated CD8+ T Cells. *Mucosal Immunol.* **2021**, *14*, 1381–1392. [[CrossRef](#)]
40. Houser, M.C.; Tansey, M.G. The Gut-Brain Axis: Is Intestinal Inflammation a Silent Driver of Parkinson's Disease Pathogenesis? *NPJ Park. Dis.* **2017**, *3*, 3. [[CrossRef](#)]
41. Politi, L.S.; Salsano, E.; Grimaldi, M. Magnetic Resonance Imaging Alteration of the Brain in a Patient With Coronavirus Disease 2019 (COVID-19) and Anosmia. *JAMA Neurol.* **2020**, *77*, 1028. [[CrossRef](#)] [[PubMed](#)]
42. Tsvigoulis, G.; Palaiodimou, L.; Katsanos, A.H.; Caso, V.; Köhrmann, M.; Molina, C.; Cordonnier, C.; Fischer, U.; Kelly, P.; Sharma, V.K.; et al. Neurological Manifestations and Implications of COVID-19 Pandemic. *Ther. Adv. Neurol. Disord.* **2020**, *13*, 175628642093203. [[CrossRef](#)] [[PubMed](#)]
43. Tsvigoulis, G.; Fragkou, P.C.; Lachanis, S.; Palaiodimou, L.; Lambadiari, V.; Papathanasiou, M.; Sfikakis, P.P.; Voumvourakis, K.I.; Tsiodras, S. Olfactory Bulb and Mucosa Abnormalities in Persistent COVID-19-induced Anosmia: A Magnetic Resonance Imaging Study. *Eur. J. Neurol.* **2021**, *28*, e6–e8. [[CrossRef](#)] [[PubMed](#)]
44. Tsvigoulis, G.; Fragkou, P.C.; Karofylakis, E.; Paneta, M.; Papathanasiou, K.; Palaiodimou, L.; Psarros, C.; Papathanasiou, M.; Lachanis, S.; Sfikakis, P.P.; et al. Hypothyroidism Is Associated with Prolonged COVID-19-Induced Anosmia: A Case–Control Study. *J. Neurol. Neurosurg. Psychiatry* **2021**, *92*, 911–912. [[CrossRef](#)]
45. Stefanou, M.-I.; Palaiodimou, L.; Bakola, E.; Smyrnis, N.; Papadopoulou, M.; Paraskevas, G.P.; Rizos, E.; Boutati, E.; Grigoriadis, N.; Krogias, C.; et al. Neurological Manifestations of Long-COVID Syndrome: A Narrative Review. *Ther. Adv. Chronic Dis.* **2022**, *13*, 204062232210768. [[CrossRef](#)]
46. Welcome, M.O.; Mastorakis, N.E. Neuropathophysiology of Coronavirus Disease 2019: Neuroinflammation and Blood Brain Barrier Disruption Are Critical Pathophysiological Processes That Contribute to the Clinical Symptoms of SARS-CoV-2 Infection. *Inflammopharmacology* **2021**, *29*, 939–963. [[CrossRef](#)]
47. Chen, R.; Wang, K.; Yu, J.; Howard, D.; French, L.; Chen, Z.; Wen, C.; Xu, Z. The Spatial and Cell-Type Distribution of SARS-CoV-2 Receptor ACE2 in Human and Mouse Brain. *BioRxiv* **2020**. [[CrossRef](#)]
48. Buzhdygan, T.P.; DeOre, B.J.; Baldwin-Leclair, A.; Bullock, T.A.; McGary, H.M.; Khan, J.A.; Razmpour, R.; Hale, J.F.; Galie, P.A.; Potula, R.; et al. The SARS-CoV-2 Spike Protein Alters Barrier Function in 2D Static and 3D Microfluidic in-Vitro Models of the Human Blood–Brain Barrier. *Neurobiol. Dis.* **2020**, *146*, 105131. [[CrossRef](#)]
49. Picca, A.; Calvani, R.; Coelho-Junior, H.J.; Landi, F.; Bernabei, R.; Marzetti, E. Mitochondrial Dysfunction, Oxidative Stress, and Neuroinflammation: Intertwined Roads to Neurodegeneration. *Antioxidants* **2020**, *9*, 647. [[CrossRef](#)]
50. Sulzer, D.; Antonini, A.; Leta, V.; Nordvig, A.; Smeyne, R.J.; Goldman, J.E.; Al-Dalahmah, O.; Zecca, L.; Sette, A.; Bubacco, L.; et al. COVID-19 and Possible Links with Parkinson's Disease and Parkinsonism: From Bench to Bedside. *NPJ Park. Dis.* **2020**, *6*, 18. [[CrossRef](#)]
51. Chaudhry, Z.; Klenja, D.; Janjua, N.; Cami-Kobeci, G.; Ahmed, B. COVID-19 and Parkinson's Disease: Shared Inflammatory Pathways Under Oxidative Stress. *Brain Sci.* **2020**, *10*, 807. [[CrossRef](#)] [[PubMed](#)]
52. Serrano-Castro, P.J.; Estivill-Torrús, G.; Cabezudo-García, P.; Reyes-Bueno, J.A.; Ciano Petersen, N.; Aguilar-Castillo, M.J.; Suárez-Pérez, J.; Jiménez-Hernández, M.D.; Moya-Molina, M.Á.; Oliver-Martos, B.; et al. Impact of SARS-CoV-2 Infection on Neurodegenerative and Neuropsychiatric Diseases: A Delayed Pandemic? *Neurología* **2020**, *35*, 245–251. [[CrossRef](#)]
53. Cavezzi, A.; Troiani, E.; Corrao, S. COVID-19: Hemoglobin, Iron, and Hypoxia beyond Inflammation. A Narrative Review. *Clin. Pract.* **2020**, *10*, 1271. [[CrossRef](#)]
54. Idrees, D.; Kumar, V. SARS-CoV-2 Spike Protein Interactions with Amyloidogenic Proteins: Potential Clues to Neurodegeneration. *Biochem. Biophys. Res. Commun.* **2021**, *554*, 94–98. [[CrossRef](#)] [[PubMed](#)]
55. Aranda-Rivera, A.K.; Cruz-Gregorio, A.; Pedraza-Chaverri, J.; Scholze, A. Nrf2 Activation in Chronic Kidney Disease: Promises and Pitfalls. *Antioxidants* **2022**, *11*, 1112. [[CrossRef](#)]
56. Horie, Y.; Suzuki, T.; Inoue, J.; Iso, T.; Wells, G.; Moore, T.W.; Mizushima, T.; Dinkova-Kostova, A.T.; Kasai, T.; Kamei, T.; et al. Molecular Basis for the Disruption of Keap1–Nrf2 Interaction via Hinge & Latch Mechanism. *Commun. Biol.* **2021**, *4*, 576. [[CrossRef](#)] [[PubMed](#)]
57. Aranda-Rivera, A.K.; Cruz-Gregorio, A.; Arancibia-Hernández, Y.L.; Hernández-Cruz, E.Y.; Pedraza-Chaverri, J. RONS and Oxidative Stress: An Overview of Basic Concepts. *Oxygen* **2022**, *2*, 437–478. [[CrossRef](#)]

58. Baird, L.; Yamamoto, M. The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway. *Mol. Cell. Biol.* **2020**, *40*, e00099-20. [[CrossRef](#)]
59. Olagnier, D.; Farahani, E.; Thyrsted, J.; Blay-Cadanet, J.; Herengt, A.; Idorn, M.; Hait, A.; Hernaez, B.; Knudsen, A.; Iversen, M.B.; et al. SARS-CoV2-Mediated Suppression of NRF2-Signaling Reveals Potent Antiviral and Anti-Inflammatory Activity of 4-Octyl-Itaconate and Dimethyl Fumarate. *Nat. Commun.* **2020**, *11*, 4938. [[CrossRef](#)]
60. Klotz, L.-O.; Sánchez-Ramos, C.; Prieto-Arroyo, I.; Urbánek, P.; Steinbrenner, H.; Monsalve, M. Redox Regulation of FoxO Transcription Factors. *Redox Biol.* **2015**, *6*, 51–72. [[CrossRef](#)]
61. Borniquel, S.; García-Quintáns, N.; Valle, I.; Olmos, Y.; Wild, B.; Martínez-Granero, F.; Soria, E.; Lamas, S.; Monsalve, M. Inactivation of Foxo3a and Subsequent Downregulation of PGC-1 α Mediate Nitric Oxide-Induced Endothelial Cell Migration. *Mol. Cell. Biol.* **2010**, *30*, 4035–4044. [[CrossRef](#)] [[PubMed](#)]
62. Li, X.; Monks, B.; Ge, Q.; Birnbaum, M.J. Akt/PKB Regulates Hepatic Metabolism by Directly Inhibiting PGC-1 α Transcription Coactivator. *Nature* **2007**, *447*, 1012–1016. [[CrossRef](#)] [[PubMed](#)]
63. Wu, M.; Bian, Q.; Liu, Y.; Fernandes, A.; Taylor, A.; Pereira, P.; Shang, F. Sustained Oxidative Stress Inhibits NF-KB Activation Partially via Inactivating the Proteasome. *Free Radic. Biol. Med.* **2009**, *46*, 62–69. [[CrossRef](#)] [[PubMed](#)]
64. Andrzejewski, K.; Jampolska, M.; Zaremba, M.; Joniec-Maciejak, I.; Boguszewski, P.M.; Kaczyńska, K. Respiratory Pattern and Phrenic and Hypoglossal Nerve Activity during Normoxia and Hypoxia in 6-OHDA-Induced Bilateral Model of Parkinson's Disease. *J. Physiol. Sci.* **2020**, *70*, 16. [[CrossRef](#)] [[PubMed](#)]
65. Deumens, R.; Blokland, A.; Prickaerts, J. Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway. *Exp. Neurol.* **2002**, *175*, 303–317. [[CrossRef](#)] [[PubMed](#)]
66. Glinka, Y.Y.; Youdim, M.B.H. Inhibition of Mitochondrial Complexes I and IV by 6-Hydroxydopamine. *Eur. J. Pharmacol. Environ. Toxicol. Pharmacol.* **1995**, *292*, 329–332. [[CrossRef](#)]
67. Tanaka, K.; Ogawa, N.; Asanuma, M. Molecular Basis of 6-Hydroxydopamine-Induced Caspase Activations Due to Increases in Oxidative Stress in the Mouse Striatum. *Neurosci. Lett.* **2006**, *410*, 85–89. [[CrossRef](#)]
68. Tirmenstein, M.A.; Hu, C.X.; Scicchitano, M.S.; Narayanan, P.K.; McFarland, D.C.; Thomas, H.C.; Schwartz, L.W. Effects of 6-Hydroxydopamine on Mitochondrial Function and Glutathione Status in SH-SY5Y Human Neuroblastoma Cells. *Toxicol. Vitro.* **2005**, *19*, 471–479. [[CrossRef](#)]
69. Blum, D.; Torch, S.; Lambeng, N.; Nissou, M.-F.; Benabid, A.-L.; Sadoul, R.; Verna, J.-M. Molecular Pathways Involved in the Neurotoxicity of 6-OHDA, Dopamine and MPTP: Contribution to the Apoptotic Theory in Parkinson's Disease. *Prog. Neurobiol.* **2001**, *65*, 135–172. [[CrossRef](#)]
70. Gong, P.; Deng, F.; Zhang, W.; Ji, J.; Liu, J.; Sun, Y.; Hu, J. Tectorigenin Attenuates the MPP⁺-induced SH-SY5Y Cell Damage, Indicating a Potential Beneficial Role in Parkinson's Disease by Oxidative Stress Inhibition. *Exp. Ther. Med.* **2017**, *14*, 4431–4437. [[CrossRef](#)]
71. Vestuto, V.; Amodio, G.; Pepe, G.; Basilicata, M.G.; Belvedere, R.; Napolitano, E.; Guarnieri, D.; Pagliara, V.; Paladino, S.; Rodriguez, M.; et al. Cocoa Extract Provides Protection against 6-OHDA Toxicity in SH-SY5Y Dopaminergic Neurons by Targeting PERK. *Biomedicines* **2022**, *10*, 2009. [[CrossRef](#)]
72. Chansiw, N.; Kulprachakarn, K.; Paradee, N.; Prommaban, A.; Srichairatanakool, S. Protection of Iron-Induced Oxidative Damage in Neuroblastoma (SH-SY5Y) Cells by Combination of 1-(N-Acetyl-6-Aminoethyl)-3-Hydroxy-2-Methylpyridin-4-One and Green Tea Extract. *Bioinorg. Chem. Appl.* **2021**, *2021*, 5539666. [[CrossRef](#)]
73. Chen, D.; Kanthasamy, A.G.; Reddy, M.B. EGCG Protects against 6-OHDA-Induced Neurotoxicity in a Cell Culture Model. *Park. Dis.* **2015**, *2015*, 843906. [[CrossRef](#)]
74. Semenza, G.L. HIF-1: Mediator of Physiological and Pathophysiological Responses to Hypoxia. *J. Appl. Physiol.* **2000**, *88*, 1474–1480. [[CrossRef](#)]
75. Chazelas, P.; Steichen, C.; Favreau, F.; Trouillas, P.; Hannaert, P.; Thuillier, R.; Giraud, S.; Hauet, T.; Guillard, J. Oxidative Stress Evaluation in Ischemia Reperfusion Models: Characteristics, Limits and Perspectives. *IJMS* **2021**, *22*, 2366. [[CrossRef](#)]
76. Irani, K. Oxidant Signaling in Vascular Cell Growth, Death, and Survival: A Review of the Roles of Reactive Oxygen Species in Smooth Muscle and Endothelial Cell Mitogenic and Apoptotic Signaling. *Circ. Res.* **2000**, *87*, 179–183. [[CrossRef](#)]
77. Saikumar, P.; Dong, Z.; Weinberg, J.M.; Venkatachalam, M.A. Mechanisms of Cell Death in Hypoxia/Reoxygenation Injury. *Oncogene* **1998**, *17*, 3341–3349. [[CrossRef](#)]
78. Klein, C.; Westenberger, A. Genetics of Parkinson's Disease. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a008888. [[CrossRef](#)]
79. Martin, I.; Dawson, V.L.; Dawson, T.M. Recent Advances in the Genetics of Parkinson's Disease. *Annu. Rev. Genom. Hum. Genet.* **2011**, *12*, 301–325. [[CrossRef](#)]
80. Scott, L.; Dawson, V.L.; Dawson, T.M. Trumping Neurodegeneration: Targeting Common Pathways Regulated by Autosomal Recessive Parkinson's Disease Genes. *Exp. Neurol.* **2017**, *298*, 191–201. [[CrossRef](#)]
81. Ittner, L.M.; Halliday, G.M.; Kril, J.J.; Götz, J.; Hodges, J.R.; Kiernan, M.C. FTD and ALS—Translating Mouse Studies into Clinical Trials. *Nat. Rev. Neurol.* **2015**, *11*, 360–366. [[CrossRef](#)]
82. Haass, C.; Strooper, B.D. The Presenilins in Alzheimer's Disease—Proteolysis Holds the Key. *Science* **1999**, *286*, 916–919. [[CrossRef](#)]
83. Dawson, T.M.; Golde, T.E.; Lagier-Tourenne, C. Animal Models of Neurodegenerative Diseases. *Nat. Neurosci.* **2018**, *21*, 1370–1379. [[CrossRef](#)]

84. Johnson, T.E.; de Castro, E.; Hegi de Castro, S.; Cypser, J.; Henderson, S.; Tedesco, P. Relationship between Increased Longevity and Stress Resistance as Assessed through Gerontogene Mutations in *Caenorhabditis Elegans*. *Exp. Gerontol.* **2001**, *36*, 1609–1617. [[CrossRef](#)]
85. Melov, S. Animal Models of Oxidative Stress, Aging, and Therapeutic Antioxidant Interventions. *Int. J. Biochem. Cell Biol.* **2002**, *34*, 1395–1400. [[CrossRef](#)]
86. Larsen, P.L. Aging and Resistance to Oxidative Damage in *Caenorhabditis Elegans*. *Proc. Natl. Acad. Sci. USA* **1993**, *90*, 8905–8909. [[CrossRef](#)]
87. Johnson, T.E. Increased Life-Span of Age-1 Mutants in *Caenorhabditis Elegans* and Lower Gompertz Rate of Aging. *Science* **1990**, *249*, 908–912. [[CrossRef](#)]
88. Chang, H.-C.; Liu, K.-F.; Teng, C.-J.; Lai, S.-C.; Yang, S.-E.; Ching, H.; Wu, C.-R. Sophora Tomentosa Extract Prevents MPTP-Induced Parkinsonism in C57BL/6 Mice Via the Inhibition of GSK-3 β Phosphorylation and Oxidative Stress. *Nutrients* **2019**, *11*, 252. [[CrossRef](#)]
89. Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic Systemic Pesticide Exposure Reproduces Features of Parkinson's Disease. *Nat. Neurosci.* **2000**, *3*, 1301–1306. [[CrossRef](#)]
90. Yang, W.; Tiffany-Castiglioni, E.; Lee, M.-Y.; Son, I.-H. Paraquat Induces Cyclooxygenase-2 (COX-2) Implicated Toxicity in Human Neuroblastoma SH-SY5Y Cells. *Toxicol. Lett.* **2010**, *199*, 239–246. [[CrossRef](#)]
91. Rakotoarisoa, M.; Angelov, B.; Garamus, V.M.; Angelova, A. Curcumin- and Fish Oil-Loaded Spongosome and Cubosome Nanoparticles with Neuroprotective Potential against H₂O₂-Induced Oxidative Stress in Differentiated Human SH-SY5Y Cells. *ACS Omega* **2019**, *4*, 3061–3073. [[CrossRef](#)]
92. Ransy, C.; Vaz, C.; Lombès, A.; Bouillaud, F. Use of H₂O₂ to Cause Oxidative Stress, the Catalase Issue. *IJMS* **2020**, *21*, 9149. [[CrossRef](#)]
93. Kwon, S.-H.; Lee, S.R.; Park, Y.J.; Ra, M.; Lee, Y.; Pang, C.; Kim, K.H. Suppression of 6-Hydroxydopamine-Induced Oxidative Stress by Hyperoside Via Activation of Nrf2/HO-1 Signaling in Dopaminergic Neurons. *IJMS* **2019**, *20*, 5832. [[CrossRef](#)]
94. Murphy, T.H.; Miyamoto, M.; Sastre, A.; Schnaar, R.L.; Coyle, J.T. Glutamate Toxicity in a Neuronal Cell Line Involves Inhibition of Cystine Transport Leading to Oxidative Stress. *Neuron* **1989**, *2*, 1547–1558. [[CrossRef](#)]
95. Salińska, E.; Danyś, W.; Łazarewicz, J.W. The Role of Excitotoxicity in Neurodegeneration. *Folia Neuropathol.* **2005**, *43*, 322–339.
96. Kumar, P.; Kalonia, H.; Kumar, A. Novel Protective Mechanisms of Antidepressants against 3-Nitropropionic Acid Induced Huntington's-like Symptoms: A Comparative Study. *J. Psychopharmacol.* **2011**, *25*, 1399–1411. [[CrossRef](#)]
97. Salvi, A.; Patki, G.; Khan, E.; Asghar, M.; Salim, S. Protective Effect of Tempol on Buthionine Sulfoximine-Induced Mitochondrial Impairment in Hippocampal Derived HT22 Cells. *Oxidative Med. Cell. Longev.* **2016**, *2016*, 5059043. [[CrossRef](#)]
98. Rakotoarisoa, M.; Angelov, B.; Drechsler, M.; Nicolas, V.; Bizien, T.; Gorshkova, Y.E.; Deng, Y.; Angelova, A. Liquid Crystalline Lipid Nanoparticles for Combined Delivery of Curcumin, Fish Oil and BDNF: In Vitro Neuroprotective Potential in a Cellular Model of Tunicamycin-Induced Endoplasmic Reticulum Stress. *Smart Mater. Med.* **2022**, *3*, 274–288. [[CrossRef](#)]
99. Martin, I.; Jones, M.A.; Rhodenizer, D.; Zheng, J.; Warrick, J.M.; Seroude, L.; Grotewiel, M. Sod2 Knockdown in the Musculature Has Whole-Organism Consequences in *Drosophila*. *Free Radic. Biol. Med.* **2009**, *47*, 803–813. [[CrossRef](#)]
100. Nowak, A.; Kojder, K.; Zielonka-Brzezicka, J.; Wróbel, J.; Bosiacki, M.; Fabiańska, M.; Wróbel, M.; Sołek-Pastuszka, J.; Klimowicz, A. The Use of Ginkgo Biloba L. as a Neuroprotective Agent in the Alzheimer's Disease. *Front. Pharmacol.* **2021**, *12*, 775034. [[CrossRef](#)]
101. Bradley, P.R. (Ed.) *British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs*; British Herbal Medicine Association: Bournemouth, UK, 1992.
102. Yang, Y.; Liu, P.; Chen, L.; Liu, Z.; Zhang, H.; Wang, J.; Sun, X.; Zhong, W.; Wang, N.; Tian, K.; et al. Therapeutic Effect of Ginkgo Biloba Polysaccharide in Rats with Focal Cerebral Ischemia/Reperfusion (I/R) Injury. *Carbohydr. Polym.* **2013**, *98*, 1383–1388. [[CrossRef](#)]
103. Achete de Souza, G.; de Marqui, S.V.; Matias, J.N.; Guiguer, E.L.; Barbalho, S.M. Effects of Ginkgo Biloba on Diseases Related to Oxidative Stress. *Planta Med.* **2020**, *86*, 376–386. [[CrossRef](#)]
104. Trebatická, J.; Ďuračková, Z. Psychiatric Disorders and Polyphenols: Can They Be Helpful in Therapy? *Oxidative Med. Cell. Longev.* **2015**, *2015*, 248529. [[CrossRef](#)]
105. Malik, J.; Choudhary, S.; Kumar, P. Plants and Phytochemicals for Huntington's Disease. *Pharmacogn. Rev.* **2013**, *7*, 81. [[CrossRef](#)]
106. Ren, J.; Lu, Y.; Qian, Y.; Chen, B.; Wu, T.; Ji, G. Recent Progress Regarding Kaempferol for the Treatment of Various Diseases (Review). *Exp. Ther. Med.* **2019**, *18*, 2759–2776. [[CrossRef](#)]
107. Zhou, M.; Ren, H.; Han, J.; Wang, W.; Zheng, Q.; Wang, D. Protective Effects of Kaempferol against Myocardial Ischemia/Reperfusion Injury in Isolated Rat Heart via Antioxidant Activity and Inhibition of Glycogen Synthase Kinase-3 β . *Oxidative Med. Cell. Longev.* **2015**, *2015*, 481405. [[CrossRef](#)]
108. Yang, C.-C.; Hsiao, L.-D.; Wang, C.-Y.; Lin, W.-N.; Shih, Y.-F.; Chen, Y.-W.; Cho, R.-L.; Tseng, H.-C.; Yang, C.-M. HO-1 Upregulation by Kaempferol via ROS-Dependent Nrf2-ARE Cascade Attenuates Lipopolysaccharide-Mediated Intercellular Cell Adhesion Molecule-1 Expression in Human Pulmonary Alveolar Epithelial Cells. *Antioxidants* **2022**, *11*, 782. [[CrossRef](#)]
109. Zhou, L.J.; Zhu, X.Z. Reactive Oxygen Species-Induced Apoptosis in PC12 Cells and Protective Effect of Bilobalide. *J. Pharmacol. Exp. Ther.* **2000**, *293*, 982–988.

110. Ma, T.; Lv, L.; Yu, Y.; Jia, L.; Song, X.; Xu, X.; Li, T.; Sheng, X.; Wang, H.; Zhang, J.; et al. Bilobalide Exerts Anti-Inflammatory Effects on Chondrocytes Through the AMPK/SIRT1/MTOR Pathway to Attenuate ACLT-Induced Post-Traumatic Osteoarthritis in Rats. *Front. Pharmacol.* **2022**, *13*, 783506. [CrossRef]
111. Wang, F.; Huang, J.; Li, J.; Chen, K.; Zhang, X.; Zhang, Y.; Zhu, Y. Bilobalide, a Bioactive Compound on Sepsis-Induced Acute Lung Injury through Its Anti-Inflammatory and Antioxidative Activity. *Pharmacogn. Mag.* **2021**, *17*, 163. [CrossRef]
112. Tchanchou, F.; Lacor, P.N.; Cao, Z.; Lao, L.; Hou, Y.; Cui, C.; Klein, W.L.; Luo, Y. Stimulation of Neurogenesis and Synaptogenesis by Bilobalide and Quercetin via Common Final Pathway in Hippocampal Neurons. *JAD* **2009**, *18*, 787–798. [CrossRef] [PubMed]
113. Zhou, J.-M.; Gu, S.-S.; Mei, W.H.; Zhou, J.; Wang, Z.Z.; Xiao, W. Ginkgolides and Bilobalide Protect BV2 Microglia Cells against OGD/Reoxygenation Injury by Inhibiting TLR2/4 Signaling Pathways. *Cell Stress Chaperones* **2016**, *21*, 1037–1053. [CrossRef] [PubMed]
114. Jiang, H.; Qu, P. Effects of Ginkgo Biloba Leaf Extract on Local Renin-Angiotensin System through TLR4/NF-KB Pathway in Cardiac Myocyte. *Exp. Ther. Med.* **2017**, *14*, 5857–5862. [CrossRef]
115. He, G.; Yuan, C.; Hao, L.; Xu, Y.; Zhang, Z. GBE50 Attenuates Inflammatory Response by Inhibiting the P38 MAPK and NF- κ B Pathways in LPS-Stimulated Microglial Cells. *Evid. Based Complement. Altern. Med.* **2014**, *2014*, 368598. [CrossRef]
116. Liu, F.-Q.; Gao, Q.; Wang, D.-D.; Zhang, Z.-X. Effects of GBE50 on LPS/ATP induced NLRP3 inflammasome activation in primary rat microglia. *China J. Chin. Mater. Med.* **2018**, *43*, 3346–3352. [CrossRef]
117. Gong, G.; Guan, Y.-Y.; Zhang, Z.-L.; Rahman, K.; Wang, S.-J.; Zhou, S.; Luan, X.; Zhang, H. Isorhamnetin: A Review of Pharmacological Effects. *Biomed. Pharmacother.* **2020**, *128*, 110301. [CrossRef]
118. Derosa, G.; Maffioli, P.; D'Angelo, A.; Di Pierro, F. A Role for Quercetin in Coronavirus Disease 2019 (COVID-19). *Phytother. Res.* **2021**, *35*, 1230–1236. [CrossRef]
119. Liu, Q.; Jin, Z.; Xu, Z.; Yang, H.; Li, L.; Li, G.; Li, F.; Gu, S.; Zong, S.; Zhou, J.; et al. Antioxidant Effects of Ginkgolides and Bilobalide against Cerebral Ischemia Injury by Activating the Akt/Nrf2 Pathway in Vitro and in Vivo. *Cell Stress Chaperones* **2019**, *24*, 441–452. [CrossRef]
120. Kaur, N.; Dhiman, M.; Perez-Polo, J.R.; Mantha, A.K. Ginkgolide B Revamps Neuroprotective Role of Apurinic/Apyrimidinic Endonuclease 1 and Mitochondrial Oxidative Phosphorylation against A β ₂₅₋₃₅-Induced Neurotoxicity in Human Neuroblastoma Cells: Neuroprotective Role of APE1. *J. Neurosci. Res.* **2015**, *93*, 938–947. [CrossRef]
121. Lin, H.; Guo, X.; Zhang, S.; Dial, S.L.; Guo, L.; Manjanatha, M.G.; Moore, M.M.; Mei, N. Mechanistic Evaluation of Ginkgo Biloba Leaf Extract-Induced Genotoxicity in L5178Y Cells. *Toxicol. Sci.* **2014**, *139*, 338–349. [CrossRef]
122. Parimoo, H.A.; Sharma, R.; Patil, R.D.; Sharma, O.P.; Kumar, P.; Kumar, N. Hepatoprotective Effect of Ginkgo Biloba Leaf Extract on Lantadenes-Induced Hepatotoxicity in Guinea Pigs. *Toxicol.* **2014**, *81*, 1–12. [CrossRef] [PubMed]
123. Xiao, Q.; Wang, C.; Li, J.; Hou, Q.; Li, J.; Ma, J.; Wang, W.; Wang, Z. Ginkgolide B Protects Hippocampal Neurons from Apoptosis Induced by Beta-Amyloid 25–35 Partly via up-Regulation of Brain-Derived Neurotrophic Factor. *Eur. J. Pharmacol.* **2010**, *647*, 48–54. [CrossRef] [PubMed]
124. Liou, C.-J.; Lai, X.-Y.; Chen, Y.-L.; Wang, C.-L.; Wei, C.-H.; Huang, W.-C. Ginkgolide C Suppresses Adipogenesis in 3T3-L1 Adipocytes via the AMPK Signaling Pathway. *Evid. Based Complement. Altern. Med.* **2015**, *2015*, 298635. [CrossRef] [PubMed]
125. Huang, W.-C.; Chen, Y.-L.; Liu, H.-C.; Wu, S.-J.; Liou, C.-J. Ginkgolide C Reduced Oleic Acid-Induced Lipid Accumulation in HepG2 Cells. *Saudi Pharm. J.* **2018**, *26*, 1178–1184. [CrossRef] [PubMed]
126. Zhang, R.; Han, D.; Li, Z.; Shen, C.; Zhang, Y.; Li, J.; Yan, G.; Li, S.; Hu, B.; Li, J.; et al. Ginkgolide C Alleviates Myocardial Ischemia/Reperfusion-Induced Inflammatory Injury via Inhibition of CD40-NF-KB Pathway. *Front. Pharmacol.* **2018**, *9*, 109. [CrossRef]
127. Zhao, M.; Qin, J.; Shen, W.; Wu, A. Bilobalide Enhances AMPK Activity to Improve Liver Injury and Metabolic Disorders in STZ-Induced Diabetes in Immature Rats via Regulating HMGB1/TLR4/NF-KB Signaling Pathway. *BioMed Res. Int.* **2021**, *2021*, 8835408. [CrossRef]
128. Lu, L.; Wang, S.; Fu, L.; Liu, D.; Zhu, Y.; Xu, A. Bilobalide Protection of Normal Human Melanocytes from Hydrogen Peroxide-Induced Oxidative Damage via Promotion of Antioxidase Expression and Inhibition of Endoplasmic Reticulum Stress. *Clin. Exp. Dermatol.* **2016**, *41*, 64–73. [CrossRef]
129. Serrano-García, N.; Pedraza-Chaverri, J.; Mares-Sámano, J.J.; Orozco-Ibarra, M.; Cruz-Salgado, A.; Jiménez-Anguiano, A.; Sotelo, J.; Trejo-Solís, C. Antiapoptotic Effects of EGb 761. *Evid. Based Complement. Altern. Med.* **2013**, *2013*, 495703. [CrossRef]
130. Ku, S.-K.; Kim, T.H.; Bae, J.-S. Anticoagulant Activities of Persicarin and Isorhamnetin. *Vasc. Pharmacol.* **2013**, *58*, 272–279. [CrossRef]
131. Yang, J.H.; Shin, B.Y.; Han, J.Y.; Kim, M.G.; Wi, J.E.; Kim, Y.W.; Cho, I.J.; Kim, S.C.; Shin, S.M.; Ki, S.H. Isorhamnetin Protects against Oxidative Stress by Activating Nrf2 and Inducing the Expression of Its Target Genes. *Toxicol. Appl. Pharmacol.* **2014**, *274*, 293–301. [CrossRef]
132. Mango, D.; Weisz, F.; Nisticò, R. Ginkgolic Acid Protects against A β -Induced Synaptic Dysfunction in the Hippocampus. *Front. Pharmacol.* **2016**, *7*, 401. [CrossRef] [PubMed]
133. Vijayakumar, S.; Nakamura, Y.; Henley, J.M.; Pountney, D.L. Ginkgolic Acid Promotes Autophagy-Dependent Clearance of Intracellular Alpha-Synuclein Aggregates. *Mol. Cell. Neurosci.* **2019**, *101*, 103416. [CrossRef] [PubMed]
134. Boots, A.W.; Drent, M.; de Boer, V.C.J.; Bast, A.; Haenen, G.R.M.M. Quercetin Reduces Markers of Oxidative Stress and Inflammation in Sarcoidosis. *Clin. Nutr.* **2011**, *30*, 506–512. [CrossRef] [PubMed]

135. Chen, S.; Jiang, H.; Wu, X.; Fang, J. Therapeutic Effects of Quercetin on Inflammation, Obesity, and Type 2 Diabetes. *Mediat. Inflamm.* **2016**, *2016*, 9343460. [[CrossRef](#)] [[PubMed](#)]
136. Wang, J.; Zhang, L.; Zhang, Y.; Luo, M.; Wu, Q.; Yu, L.; Chu, H. Transcriptional Upregulation of HO-1 by EGB via the MAPKs/Nrf2 Pathway in Mouse C2C12 Myoblasts. *Toxicol. Vitro.* **2015**, *29*, 380–388. [[CrossRef](#)]
137. Ali, F.; Rahul, J.; Jyoti, S.; Naz, F.; Ashafaq, M.; Shahid, M.; Siddique, Y.H. Therapeutic Potential of Luteolin in Transgenic Drosophila Model of Alzheimer's Disease. *Neurosci. Lett.* **2019**, *692*, 90–99. [[CrossRef](#)]
138. Luo, Y.; Shang, P.; Li, D. Luteolin: A Flavonoid That Has Multiple Cardio-Protective Effects and Its Molecular Mechanisms. *Front. Pharmacol.* **2017**, *8*, 692. [[CrossRef](#)]
139. Smith, J.V.; Burdick, A.J.; Golik, P.; Khan, I.; Wallace, D.; Luo, Y. Anti-Apoptotic Properties of Ginkgo Biloba Extract EGb 761 in Differentiated PC12 Cells. *Cell. Mol. Biol.* **2002**, *48*, 699–707.
140. Perianayagam, M.C.; Madias, N.E.; Pereira, B.J.G.; Jaber, B.L. CREB Transcription Factor Modulates Bcl2 Transcription in Response to C5a in HL-60-Derived Neutrophils. *Eur. J. Clin. Invest.* **2006**, *36*, 353–361. [[CrossRef](#)]
141. Tchanchou, F.; Xu, Y.; Wu, Y.; Christen, Y.; Luo, Y. EGb 761 Enhances Adult Hippocampal Neurogenesis and Phosphorylation of CREB in Transgenic Mouse Model of Alzheimer's Disease. *FASEB J.* **2007**, *21*, 2400–2408. [[CrossRef](#)]
142. Hao, F.; Li, A.; Yu, H.; Liu, M.; Wang, Y.; Liu, J.; Liang, Z. Enhanced Neuroprotective Effects of Combination Therapy with Bone Marrow-Derived Mesenchymal Stem Cells and Ginkgo Biloba Extract (EGb761) in a Rat Model of Experimental Autoimmune Encephalomyelitis. *Neuroimmunomodulation* **2016**, *23*, 41–57. [[CrossRef](#)] [[PubMed](#)]
143. Du, X.; Wang, X.; Geng, M. Alzheimer's Disease Hypothesis and Related Therapies. *Transl. Neurodegener.* **2018**, *7*, 2. [[CrossRef](#)]
144. Andersson, U. The Cholinergic Anti-Inflammatory Pathway Alleviates Acute Lung Injury. *Mol. Med.* **2020**, *26*, 64. [[CrossRef](#)] [[PubMed](#)]
145. Ivic, L.; Sands, T.T.J.; Fishkin, N.; Nakanishi, K.; Kriegstein, A.R.; Strömgaard, K. Terpene Trilactones from Ginkgo Biloba Are Antagonists of Cortical Glycine and GABAA Receptors. *J. Biol. Chem.* **2003**, *278*, 49279–49285. [[CrossRef](#)] [[PubMed](#)]
146. Alexandris, N.; Lagoumintzis, G.; Chasapis, C.T.; Leonidas, D.D.; Papadopoulos, G.E.; Tzartos, S.J.; Tsatsakis, A.; Eliopoulos, E.; Poulas, K.; Farsalinos, K. Nicotinic Cholinergic System and COVID-19: In Silico Evaluation of Nicotinic Acetylcholine Receptor Agonists as Potential Therapeutic Interventions. *Toxicol. Rep.* **2021**, *8*, 73–83. [[CrossRef](#)]
147. Spiegel, R.; Kalla, R.; Mantokoudis, G.; Maire, R.; Mueller, H.; Hoerr, R.; Ihl, R. Ginkgo Biloba Extract EGb 761^{Δreg} Alleviates Neurosensory Symptoms in Patients with Dementia: A Meta-Analysis of Treatment Effects on Tinnitus and Dizziness in Randomized, Placebo-Controlled Trials. *CIA* **2018**, *13*, 1121–1127. [[CrossRef](#)]
148. Di Meo, F.; Cuciniello, R.; Margarucci, S.; Bergamo, P.; Petillo, O.; Peluso, G.; Filosa, S.; Crispi, S. Ginkgo Biloba Prevents Oxidative Stress-Induced Apoptosis Blocking P53 Activation in Neuroblastoma Cells. *Antioxidants* **2020**, *9*, 279. [[CrossRef](#)]
149. Wang, L.P.; Zhang, X.Y.; Liu, N.; Ma, Z.Z.; Fang, D.S. Comparison of Integrated Traditional Chinese and Western Medicine Therapy on Vascular Cognitive Impairment with No Dementia. *Genet. Mol. Res.* **2015**, *14*, 4896–4902. [[CrossRef](#)]
150. Gschwind, Y.J.; Bridenbaugh, S.A.; Reinhard, S.; Granacher, U.; Monsch, A.U.; Kressig, R.W. Ginkgo Biloba Special Extract LI 1370 Improves Dual-Task Walking in Patients with MCI: A Randomised, Double-Blind, Placebo-Controlled Exploratory Study. *Ageing Clin. Exp. Res.* **2017**, *29*, 609–619. [[CrossRef](#)]
151. Kuo, L.-C.; Song, Y.-Q.; Yao, C.-A.; Cheng, I.H.; Chien, C.-T.; Lee, G.-C.; Yang, W.-C.; Lin, Y. Ginkgolide A Prevents the Amyloid- β -Induced Depolarization of Cortical Neurons. *J. Agric. Food Chem.* **2019**, *67*, 81–89. [[CrossRef](#)]
152. Yu, D.; Zhang, P.; Li, J.; Liu, T.; Zhang, Y.; Wang, Q.; Zhang, J.; Lu, X.; Fan, X. Neuroprotective Effects of Ginkgo Biloba Dropping Pills in Parkinson's Disease. *J. Pharm. Anal.* **2021**, *11*, 220–231. [[CrossRef](#)] [[PubMed](#)]
153. Schindowski, K.; Leutner, S.; Kressmann, S.; Eckert, A.; Müller, W.E. Age-Related Increase of Oxidative Stress-Induced Apoptosis in Mice Prevention by Ginkgo Biloba Extract (EGb761). *J. Neural Transm.* **2001**, *108*, 969–978. [[CrossRef](#)] [[PubMed](#)]
154. Shi, C.; Xiao, S.; Liu, J.; Guo, K.; Wu, F.; Yew, D.T.; Xu, J. Ginkgo Biloba Extract EGb761 Protects against Aging-Associated Mitochondrial Dysfunction in Platelets and Hippocampi of SAMP8 Mice. *Platelets* **2010**, *21*, 373–379. [[CrossRef](#)] [[PubMed](#)]
155. Wang, Y.-Q.; Wang, M.-Y.; Fu, X.-R.; Peng-Yu, G.; Gao, G.-F.; Fan, Y.-M.; Duan, X.-L.; Zhao, B.-L.; Chang, Y.-Z.; Shi, Z.-H. Neuroprotective Effects of Ginkgetin against Neuroinjury in Parkinson's Disease Model Induced by MPTP via Chelating Iron. *Free Radic. Res.* **2015**, *49*, 1069–1080. [[CrossRef](#)] [[PubMed](#)]
156. You, O.H.; Kim, S.-H.; Kim, B.; Sohn, E.J.; Lee, H.-J.; Shim, B.-S.; Yun, M.; Kwon, B.-M.; Kim, S.-H. Ginkgetin Induces Apoptosis via Activation of Caspase and Inhibition of Survival Genes in PC-3 Prostate Cancer Cells. *Bioorganic Med. Chem. Lett.* **2013**, *23*, 2692–2695. [[CrossRef](#)]
157. Rhein, V.; Giese, M.; Baysang, G.; Meier, F.; Rao, S.; Schulz, K.L.; Hamburger, M.; Eckert, A. Ginkgo Biloba Extract Ameliorates Oxidative Phosphorylation Performance and Rescues A β -Induced Failure. *PLoS ONE* **2010**, *5*, e12359. [[CrossRef](#)]
158. Adebayo, O.G.; Asiwe, J.N.; Ben-Azu, B.; Aduema, W.; Onyeleonu, I.; Akpotu, A.E.; Wopara, I.; Kolawole, T.A.; Umoren, E.B.; Igbokwe, V.; et al. Ginkgo Biloba Protects Striatal Neurodegeneration and Gut Phagoinflammatory Damage in Rotenone-induced Mice Model of Parkinson's Disease: Role of Executioner Caspase-3/Nrf2/ ARE Signaling. *J. Food Biochem.* **2022**, *46*, e14253. [[CrossRef](#)]
159. Dong, Z.-H.; Zhang, C.-Y.; Pu, B.-H. Effects of ginkgo biloba tablet in treating mild cognitive impairment. *Chin. J. Integr. Tradit. West. Med.* **2012**, *32*, 1208–1211.
160. Mahdy, H.M.; Tadros, M.G.; Mohamed, M.R.; Karim, A.M.; Khalifa, A.E. The Effect of Ginkgo Biloba Extract on 3-Nitropropionic Acid-Induced Neurotoxicity in Rats. *Neurochem. Int.* **2011**, *59*, 770–778. [[CrossRef](#)]

161. Beg, T.; Jyoti, S.; Naz, F.; Rahul; Ali, F.; Ali, S.K.; Reyad, A.M.; Siddique, Y.H. Protective Effect of Kaempferol on the Transgenic Drosophila Model of Alzheimer's Disease. *CNS Neurol. Disord. Drug Targets* **2018**, *17*, 421–429. [[CrossRef](#)]
162. Jiang, M.; Li, J.; Peng, Q.; Liu, Y.; Liu, W.; Luo, C.; Peng, J.; Li, J.; Yung, K.K.L.; Mo, Z. Neuroprotective Effects of Bilobalide on Cerebral Ischemia and Reperfusion Injury Are Associated with Inhibition of Pro-Inflammatory Mediator Production and down-Regulation of JNK1/2 and P38 MAPK Activation. *J. Neuroinflamm.* **2014**, *11*, 167. [[CrossRef](#)] [[PubMed](#)]
163. Li, W.; Chen, Z.; Yan, M.; He, P.; Chen, Z.; Dai, H. The Protective Role of Isorhamnetin on Human Brain Microvascular Endothelial Cells from Cytotoxicity Induced by Methylglyoxal and Oxygen-Glucose Deprivation. *J. Neurochem.* **2016**, *136*, 651–659. [[CrossRef](#)] [[PubMed](#)]
164. Sung, J.-H.; Shah, F.-A.; Cho, E.-H.; Gim, S.-A.; Jeon, S.-J.; Kim, K.-M.; Kim, Y.-M.; Kim, M.-O.; Koh, P.-O. *Ginkgo Biloba* Extract (EGb 761) Prevents the Ischemic Brain Injury-Induced Decrease in Parvalbumin Expression. *Lab. Anim. Res.* **2012**, *28*, 77. [[CrossRef](#)] [[PubMed](#)]
165. Huang, L.; Shi, Y.; Zhao, L. Ginkgolide B Alleviates Learning and Memory Impairment in Rats With Vascular Dementia by Reducing Neuroinflammation via Regulating NF-KB Pathway. *Front. Pharmacol.* **2021**, *12*, 676392. [[CrossRef](#)] [[PubMed](#)]
166. Li, W.; Qinghai, S.; Kai, L.; Xue, M.; Lili, N.; Jihua, R.; Zhengxiang, L.; Xiaoling, L.; Di, G.; Qi, Y.; et al. Oral Administration of Ginkgolide B Alleviates Hypoxia-Induced Neuronal Damage in Rat Hippocampus by Inhibiting Oxidative Stress and Apoptosis. *Iran. J. Basic Med. Sci.* **2019**, *22*, 140–145. [[CrossRef](#)]
167. Wang, L.; Lei, Q.; Zhao, S.; Xu, W.; Dong, W.; Ran, J.; Shi, Q.; Fu, J. Ginkgolide B Maintains Calcium Homeostasis in Hypoxic Hippocampal Neurons by Inhibiting Calcium Influx and Intracellular Calcium Release. *Front. Cell. Neurosci.* **2021**, *14*, 627846. [[CrossRef](#)]
168. Chan, P.-C.; Xia, Q.; Fu, P.P. *Ginkgo Biloba* Leave Extract: Biological, Medicinal, and Toxicological Effects. *J. Environ. Sci. Health Part C* **2007**, *25*, 211–244. [[CrossRef](#)]
169. Al-Yahya, A.A.; Al-Majed, A.A.; Al-Bekairi, A.M.; Al-Shabanah, O.A.; Qureshi, S. Studies on the Reproductive, Cytological and Biochemical Toxicity of *Ginkgo Biloba* in Swiss Albino Mice. *J. Ethnopharmacol.* **2006**, *107*, 222–228. [[CrossRef](#)]
170. Bent, S.; Goldberg, H.; Padula, A.; Avins, A.L. Spontaneous Bleeding Associated with *Ginkgo Biloba*: A Case Report and Systematic Review of the Literature: A Case Report and Systematic Review of the Literature. *J. Gen. Intern. Med.* **2005**, *20*, 657–661. [[CrossRef](#)]
171. Pedroso, J.L.; Henriques Aquino, C.C.; Escórcio Bezerra, M.L.; Baiense, R.F.; Suarez, M.M.; Dutra, L.A.; Braga-Neto, P.; Povoas Barsottini, O.G. *Ginkgo Biloba* and Cerebral Bleeding: A Case Report and Critical Review. *Neurologist* **2011**, *17*, 89–90. [[CrossRef](#)]
172. Rosenblatt, M.; Mindel, J. Spontaneous Hypyema Associated with Ingestion of *Ginkgo Biloba* Extract. *N. Engl. J. Med.* **1997**, *336*, 1108. [[CrossRef](#)] [[PubMed](#)]
173. Oken, B.S.; Storzbach, D.M.; Kaye, J.A. The Efficacy of *Ginkgo Biloba* on Cognitive Function in Alzheimer Disease. *Arch. Neurol.* **1998**, *55*, 1409. [[CrossRef](#)]
174. Jiang, L.; Su, L.; Cui, H.; Ren, J.; Li, C. *Ginkgo Biloba* Extract for Dementia: A Systematic Review. *Shanghai Arch Psychiatry* **2013**, *25*, 10–21. [[CrossRef](#)] [[PubMed](#)]
175. Bal Dit Sollier, C.; Caplain, H.; Drouet, L. No Alteration in Platelet Function or Coagulation Induced by EGb761 in a Controlled Study: No Effect of Egb761 on Platelet and Coagulation. *Clin. Lab. Haematol.* **2003**, *25*, 251–253. [[CrossRef](#)]
176. Kudolo, G.B.; Wang, W.; Barrientos, J.; Elrod, R.; Blodgett, J. The Ingestion of *Ginkgo Biloba* Extract (EGb 761) Inhibits Arachidonic Acid-Mediated Platelet Aggregation and Thromboxane B2 Production in Healthy Volunteers. *J. Herb. Pharmacother.* **2004**, *4*, 13–26. [[CrossRef](#)]
177. Snitz, B.E. *Ginkgo Biloba* for Preventing Cognitive Decline in Older Adults A Randomized Trial. *JAMA* **2009**, *302*, 2663. [[CrossRef](#)] [[PubMed](#)]
178. Solomon, P.R.; Adams, F.; Silver, A.; Zimmer, J.; DeVeaux, R. *Ginkgo* for Memory Enhancement: A Randomized Controlled Trial. *JAMA* **2002**, *288*, 835. [[CrossRef](#)] [[PubMed](#)]
179. Dodge, H.H.; Zitzelberger, T.; Oken, B.S.; Howieson, D.; Kaye, J. A Randomized Placebo-Controlled Trial of *Ginkgo Biloba* for the Prevention of Cognitive Decline. *Neurology* **2008**, *70*, 1809–1817. [[CrossRef](#)]
180. Akanchise, T.; Angelova, A. Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome. *Antioxidants* **2023**, *12*, 393. [[CrossRef](#)]
181. Li, M.; Al-Jamal, K.T.; Kostarelos, K.; Reineke, J. Physiologically Based Pharmacokinetic Modeling of Nanoparticles. *ACS Nano* **2010**, *4*, 6303–6317. [[CrossRef](#)]
182. De Matteis, V.; Rinaldi, R. Toxicity Assessment in the Nanoparticle Era. In *Cellular and Molecular Toxicology of Nanoparticles*; Saquib, Q., Faisal, M., Al-Khedhairi, A.A., Alatar, A.A., Eds.; Advances in Experimental Medicine and Biology; Springer International Publishing: Cham, Switzerland, 2018; Volume 1048, pp. 1–19. [[CrossRef](#)]
183. Ashok, A.; Andrabi, S.S.; Mansoor, S.; Kuang, Y.; Kwon, B.K.; Labhasetwar, V. Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation. *Antioxidants* **2022**, *11*, 408. [[CrossRef](#)] [[PubMed](#)]
184. Ramanathan, S.; Archunan, G.; Sivakumar, M.; Tamil Selvan, S.; Fred, A.L.; Kumar, S.; Gulyás, B.; Padmanabhan, P. Theranostic Applications of Nanoparticles in Neurodegenerative Disorders. *IJN* **2018**, *13*, 5561–5576. [[CrossRef](#)] [[PubMed](#)]
185. Gelperina, S.; Kisich, K.; Iseman, M.D.; Heifets, L. The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. *Am. J. Respir. Crit. Care Med.* **2005**, *172*, 1487–1490. [[CrossRef](#)] [[PubMed](#)]

186. Cady, R. A Novel Intranasal Breath-Powered Delivery System for Sumatriptan: A Review of Technology and Clinical Application of the Investigational Product AVP-825 in the Treatment of Migraine. *Expert Opin. Drug Deliv.* **2015**, *12*, 1565–1577. [\[CrossRef\]](#)
187. Yamada, K.; Hasegawa, M.; Kametani, S.; Ito, S. Nose-to-Brain Delivery of TS-002, Prostaglandin D₂ Analogue. *J. Drug Target.* **2007**, *15*, 59–66. [\[CrossRef\]](#)
188. Sood, S.; Jain, K.; Gowthamarajan, K. Intranasal Therapeutic Strategies for Management of Alzheimer's Disease. *J. Drug Target.* **2014**, *22*, 279–294. [\[CrossRef\]](#)
189. Sonvico, F.; Clementino, A.; Buttini, F.; Colombo, G.; Pescina, S.; Stanisçuaski Guterres, S.; Raffin Pohlmann, A.; Nicoli, S. Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting. *Pharmaceutics* **2018**, *10*, 34. [\[CrossRef\]](#)
190. Lee, D.; Minko, T. Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier. *Pharmaceutics* **2021**, *13*, 2049. [\[CrossRef\]](#)
191. Wen, Z.; Yan, Z.; Hu, K.; Pang, Z.; Cheng, X.; Guo, L.; Zhang, Q.; Jiang, X.; Fang, L.; Lai, R. Odorranalectin-Conjugated Nanoparticles: Preparation, Brain Delivery and Pharmacodynamic Study on Parkinson's Disease Following Intranasal Administration. *J. Control. Release* **2011**, *151*, 131–138. [\[CrossRef\]](#)
192. Karavelioglu, Z.; Cakir-Koc, R. Preparation of Chitosan Nanoparticles as Ginkgo Biloba Extract Carrier: In Vitro Neuroprotective Effect on Oxidative Stress-Induced Human Neuroblastoma Cells (SH-SY5Y). *Int. J. Biol. Macromol.* **2021**, *192*, 675–683. [\[CrossRef\]](#)
193. Wang, L.; Zhao, X.; Yang, F.; Wu, W.; Liu, Y.; Wang, L.; Wang, L.; Wang, Z. Enhanced Bioaccessibility *in Vitro* and Bioavailability of Ginkgo Biloba Extract Nanoparticles Prepared by Liquid Anti-solvent Precipitation. *Int. J. Food Sci. Technol.* **2019**, *54*, 2266–2276. [\[CrossRef\]](#)
194. Zhao, Y.; Xiong, S.; Liu, P.; Liu, W.; Wang, Q.; Liu, Y.; Tan, H.; Chen, X.; Shi, X.; Wang, Q.; et al. Polymeric Nanoparticles-Based Brain Delivery with Improved Therapeutic Efficacy of Ginkgolide B in Parkinson's Disease. *IJN* **2020**, *15*, 10453–10467. [\[CrossRef\]](#) [\[PubMed\]](#)
195. Dhawan, S.; Kapil, R.; Singh, B. Formulation Development and Systematic Optimization of Solid Lipid Nanoparticles of Quercetin for Improved Brain Delivery. *J. Pharm. Pharmacol.* **2011**, *63*, 342–351. [\[CrossRef\]](#) [\[PubMed\]](#)
196. Haghighi, P.; Ghaffari, S.; Arbabi Bidgoli, S.; Qomi, M.; Haghighat, S. Preparation, Characterization and Evaluation of Ginkgo Biloba Solid Lipid Nanoparticles. *Nanomed. Res. J.* **2018**, *3*, 71–78. [\[CrossRef\]](#)
197. Xu, Z.; Feng, Q.; Wang, M.; Zhao, H.; Lin, Y.; Zhou, S. Green Biosynthesized Silver Nanoparticles With Aqueous Extracts of Ginkgo Biloba Induce Apoptosis via Mitochondrial Pathway in Cervical Cancer Cells. *Front. Oncol.* **2020**, *10*, 575415. [\[CrossRef\]](#) [\[PubMed\]](#)
198. Wang, Q.; Ma, R.; Liu, P.; Cheng, G.; Yang, Q.; Chen, X.; Wu, Z.; Yuan, D.; Chen, T. Efficient Sustained-Release Nanoparticle Delivery System Protects Nigral Neurons in a Toxin Model of Parkinson's Disease. *Pharmaceutics* **2022**, *14*, 1731. [\[CrossRef\]](#)
199. Wu, X.; Huo, Q.; Quan, Q.; Yang, X.; Yu, N.; Wang, Y. Optimizing the Formulation for Ginkgolide B Solid Dispersion. *Open Life Sci.* **2018**, *13*, 253–262. [\[CrossRef\]](#)
200. Ren, Y.; Yang, H.; Wang, T.; Wang, C. Green Synthesis and Antimicrobial Activity of Monodisperse Silver Nanoparticles Synthesized Using Ginkgo Biloba Leaf Extract. *Phys. Lett. A* **2016**, *380*, 3773–3777. [\[CrossRef\]](#)
201. Osman, A.S.; Abu-Risha, S.E.; Bakr, S.M.; Altayar, A.E.; Fayad, E.; EL-Sawi, M.R.; EL-Kholy, W.M. Comparative Study between Effects of Ginkgo Biloba Extract and Extract Loaded on Gold Nanoparticles on Hepatotoxicity Induced by Potassium Bromate. *Environ. Sci. Pollut. Res.* **2023**, *30*, 5027–5036. [\[CrossRef\]](#)
202. Elshazly, E.H.; Nasr, A.; Elnosary, M.E.; Gouda, G.A.; Mohamed, H.; Song, Y. Identifying the Anti-MERS-CoV and Anti-HcoV-229E Potential Drugs from the Ginkgo Biloba Leaves Extract and Its Eco-Friendly Synthesis of Silver Nanoparticles. *Molecules* **2023**, *28*, 1375. [\[CrossRef\]](#)
203. Rifaai, R.A.; Mokhemer, S.A.; Saber, E.A.; El-Aleem, S.A.A.; El-Tahawy, N.F.G. Neuroprotective Effect of Quercetin Nanoparticles: A Possible Prophylactic and Therapeutic Role in Alzheimer's Disease. *J. Chem. Neuroanat.* **2020**, *107*, 101795. [\[CrossRef\]](#) [\[PubMed\]](#)
204. Amanzadeh Jain, E.; Esmaeili, A.; Rahgozar, S.; Noorbakhshnia, M. Quercetin-Conjugated Superparamagnetic Iron Oxide Nanoparticles Protect AlCl₃-Induced Neurotoxicity in a Rat Model of Alzheimer's Disease via Antioxidant Genes, APP Gene, and MiRNA-101. *Front. Neurosci.* **2021**, *14*, 598617. [\[CrossRef\]](#) [\[PubMed\]](#)
205. Jin, Y.; Wen, J.; Garg, S.; Zhang, W.; Teng, L.R.; Liu, D.; Zhou, Y. Development of a Novel Niosomal System for Oral Delivery of Ginkgo Biloba Extract. *IJN* **2013**, *8*, 421–430. [\[CrossRef\]](#) [\[PubMed\]](#)
206. Kazmi, I.; Al-Abbasi, F.A.; Afzal, M.; Altayb, H.N.; Nadeem, M.S.; Gupta, G. Formulation and Evaluation of Kaempferol Loaded Nanoparticles against Experimentally Induced Hepatocellular Carcinoma: In Vitro and In Vivo Studies. *Pharmaceutics* **2021**, *13*, 2086. [\[CrossRef\]](#)
207. Abbas, H.; Sayed, N.S.E.; Youssef, N.A.H.A.; Gaafar, P.M.E.; Mousa, M.R.; Fayez, A.M.; Elsheikh, M.A. Novel Luteolin-Loaded Chitosan Decorated Nanoparticles for Brain-Targeting Delivery in a Sporadic Alzheimer's Disease Mouse Model: Focus on Antioxidant, Anti-Inflammatory, and Amyloidogenic Pathways. *Pharmaceutics* **2022**, *14*, 1003. [\[CrossRef\]](#)
208. Settu, K.; Vaiyapuri, M. FORMULATION AND EVALUATION OF ISORHAMNETIN LOADED POLY LACTIC-CO-GLYCOLIC ACID NANOPARTICLES. *Asian J. Pharm. Clin. Res.* **2017**, *10*, 177. [\[CrossRef\]](#)
209. Tang, J.; Sun, J.; Cui, F.; Zhang, T.; Liu, X.; He, Z. Self-Emulsifying Drug Delivery Systems for Improving Oral Absorption of Ginkgo Biloba Extracts. *Drug Deliv.* **2008**, *15*, 477–484. [\[CrossRef\]](#)
210. Wang, T.; Wu, C.; Fan, G.; Li, T.; Gong, H.; Cao, F. Ginkgo Biloba Extracts-Loaded Starch Nano-Spheres: Preparation, Characterization, and in Vitro Release Kinetics. *Int. J. Biol. Macromol.* **2018**, *106*, 148–157. [\[CrossRef\]](#)

211. Bremer-Hoffmann, S.; Halamoda-Kenzaoui, B.; Borgos, S.E. Identification of Regulatory Needs for Nanomedicines: Regulatory Needs for Nanomedicines. *J. Interdiscip. Nanomed.* **2018**, *3*, 4–15. [[CrossRef](#)]
212. Mourdikoudis, S.; Pallares, R.M.; Thanh, N.T.K. Characterization Techniques for Nanoparticles: Comparison and Complementarity upon Studying Nanoparticle Properties. *Nanoscale* **2018**, *10*, 12871–12934. [[CrossRef](#)]
213. Faria, M.; Björnmalm, M.; Thurecht, K.J.; Kent, S.J.; Parton, R.G.; Kavallaris, M.; Johnston, A.P.R.; Gooding, J.J.; Corrie, S.R.; Boyd, B.J.; et al. Minimum Information Reporting in Bio–Nano Experimental Literature. *Nature Nanotech.* **2018**, *13*, 777–785. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.